



Morbidity and Mortality Weekly Report

www.cdc.gov/mmwr

Weekly

November 23, 2007 / Vol. 56 / No. 46

Prevalence of Regular Physical Activity Among Adults — United States, 2001 and 2005

Regular physical activity is associated with decreased risk for obesity, heart disease, hypertension, diabetes, certain cancers, and premature mortality (1). CDC and the American College of Sports Medicine recommend that adults engage in at least 30 minutes of moderate physical activity on most days and preferably on all days (2). Healthy People 2010 objectives include increasing the proportion of adults who engage regularly in moderate or vigorous activity to at least 50% (objective 22-2). In addition, reducing racial and ethnic health disparities, including disparities in physical activity, is an overarching national goal (3). To examine changes in the prevalence of regular, leisure-time, physical activity from 2001 to 2005, CDC analyzed data from the Behavioral Risk Factor Surveillance System (BRFSS). This report summarizes the results of that analysis, which indicated that, from 2001 to 2005, the prevalence of regular physical activity increased 8.6% among women overall (from 43.0% to 46.7%) and 3.5% among men (from 48.0% to 49.7%). In addition, the prevalence of regular physical activity increased 15.0% (from 31.4% to 36.1%) among non-Hispanic black women and 12.4% (from 40.3% to 45.3%) among non-Hispanic black men, slightly narrowing previous racial disparities when compared with increases of 7.8% (from 46.0% to 49.6%) for white women and 3.4% (from 50.6% to 52.3%) for white men, respectively. CDC, state and local public health agencies, and other public health partners should continue to implement evidence-based, culturally appropriate initiatives to further increase physical-activity levels among all adults, with special focus on eliminating racial/ethnic disparities.

BRFSS is a state-based, random-digit—dialed telephone survey of the noninstitutionalized, U.S. civilian population aged ≥18 years. Data for this report were reported by the 50 states, District of Columbia, Puerto Rico, and U.S.

Virgin Islands. CDC collected data for the 2001 BRFSS survey from 205,140 respondents (median response rate*: 51.1%; median cooperation rate†: 52.7%) and the 2005 survey from 356,112 respondents (median response rate: 51.1%; median cooperation rate 75.1%) (4). Response rates were calculated using guidelines from the Council of American Survey and Research Organizations.

Beginning in 2001, BRFSS included biannual questions about participation in moderate and vigorous physical activities. To assess participation in moderate activities, respondents were asked if, when not working, they "do moderate activities for at least 10 minutes at a time, such as brisk walking, bicycling, vacuuming, gardening, or anything else that causes some increase in breathing or heart rate" in a usual week. Respondents who answered "yes" were asked how many days per week they engaged in moderate activities and the amount of time spent in activities on each of those days. To assess participation in vigorous activities, respondents were asked to report whether they "do vigorous activities for at least 10 minutes at a time, such as running, aerobics, heavy yard work, or anything else that causes large increases in breathing or heart rate" in a usual week, when not working. Respondents who answered "yes" were

INSIDE

1212 Norovirus Outbreak Associated with III Food-Service Workers — Michigan, January–February 2006

1216 Notices to Readers

^{*}The percentage of persons who completed interviews among all eligible persons, including those who were not successfully contacted.

[†]The cooperation rate is the proportion of all respondents interviewed of all eligible units in which a respondent was selected and actually contacted.

The MMWR series of publications is published by the Coordinating Center for Health Information and Service, Centers for Disease Control and Prevention (CDC), U.S. Department of Health and Human Services, Atlanta, GA 30333.

Suggested Citation: Centers for Disease Control and Prevention. [Article title]. MMWR 2007;56:[inclusive page numbers].

Centers for Disease Control and Prevention

Julie L. Gerberding, MD, MPH *Director*

Tanja Popovic, MD, PhD Chief Science Officer

James W. Stephens, PhD Associate Director for Science

Steven L. Solomon, MD

Director, Coordinating Center for Health Information and Service

Jay M. Bernhardt, PhD, MPH

Director, National Center for Health Marketing

Katherine L. Daniel, PhD

Deputy Director, National Center for Health Marketing

Editorial and Production Staff

Frederic E. Shaw, MD, JD *Editor*, MMWR *Series*

Suzanne M. Hewitt, MPA

Managing Editor, MMWR Series
Douglas W. Weatherwax

Lead Technical Writer-Editor

Catherine H. Bricker, MS Jude C. Rutledge

Writers-Editors

Beverly J. Holland

Lead Visual Information Specialist

Lynda G. Cupell

Malbea A. LaPete

Visual Information Specialists

Quang M. Doan, MBA

Erica R. Shaver

Information Technology Specialists

Editorial Board

William L. Roper, MD, MPH, Chapel Hill, NC, Chairman Virginia A. Caine, MD, Indianapolis, IN David W. Fleming, MD, Seattle, WA William E. Halperin, MD, DrPH, MPH, Newark, NJ Margaret A. Hamburg, MD, Washington, DC King K. Holmes, MD, PhD, Seattle, WA Deborah Holtzman, PhD, Atlanta, GA John K. Iglehart, Bethesda, MD Dennis G. Maki, MD, Madison, WI Sue Mallonee, MPH, Oklahoma City, OK Stanley A. Plotkin, MD, Doylestown, PA Patricia Quinlisk, MD, MPH, Des Moines, IA Patrick L. Remington, MD, MPH, Madison, WI Barbara K. Rimer, DrPH, Chapel Hill, NC John V. Rullan, MD, MPH, San Juan, PR Anne Schuchat, MD, Atlanta, GA Dixie E. Snider, MD, MPH, Atlanta, GA John W. Ward, MD, Atlanta, GA

asked how many days per week they engaged in vigorous activities and the amount of time spent in activities on each of those days. For this report, respondents considered to be engaging in regular physical activity were those who met the *Healthy People 2010* objective of at least 30 minutes a day of moderate-intensity activity on 5 or more days a week, or at least 20 minutes a day of vigorous-intensity activity on 3 or more days a week, or both. Data were age adjusted to the 2000 U.S. standard population and weighted to provide overall estimates; 95% confidence intervals and p-values were calculated. Statistically significant changes in prevalence from 2001 to 2005 were determined by *t*-test (p<0.05).

From 2001 to 2005, the prevalence of regular physical activity (Table) increased by 8.6% (from 43.0% to 46.7%) among women overall and by 3.5% (from 48.0% to 49.7%) among men. Among women, significant increases in regular activity were observed in all racial/ethnic, age, and education-level categories examined with the exception of women aged 18–24 years. Among men, significant increases in regular physical activity were observed among respondents aged 45–64 years, non-Hispanic whites, non-Hispanic blacks, high school graduates, and college graduates.

Among racial/ethnic groups, significant increases in the prevalence of regular physical activity from 2001 to 2005 were observed among non-Hispanic black women (15.0%, from 31.4% to 36.1%), non-Hispanic black men (12.4%, from 40.3% to 45.3%), Hispanic women (11.6%, from 36.3% to 40.5%), women of other races (13.1%, from 41.2% to 46.6%), non-Hispanic white women (7.8%, from 46.0% to 49.6%), and non-Hispanic white men (3.4%, from 50.6% to 52.3%) (Table).

Despite certain gains, racial/ethnic disparities in physical activity remained evident in the 2005 survey results. Among men, non-Hispanic whites had the highest prevalence of regular physical activity (52.3%), followed by men classified as of other race (45.7%), non-Hispanic blacks (45.3%), and Hispanics (41.9%). Among women, non-Hispanic whites had the highest prevalence of regular physical activity (49.6%), followed by women classified as of other race (46.6%), Hispanics (40.5%), and non-Hispanic blacks (36.1%) (Table).

Reported by: J Kruger, PhD, HW Kohl III, PhD, Div of Nutrition and Physical Activity, National Center for Chronic Disease Prevention and Health Promotion; IJ Miles, ScD, EIS Officer, CDC.

Editorial Note: From 2001 to 2005, the prevalence of engaging in regular physical activity increased among both U.S. men and women. In 2005, 49.7% of men and 46.7%

TABLE. Estimated age-adjusted percentage of persons aged ≥18 years who reported meeting the *Healthy People 2010* objective for regular physical activity,* by sex, age group, race/ethnicity, and education level — Behavioral Risk Factor Surveillance System, United States, 2001 and 2005

			Mei	n				Wom	en	
		2001		2005	% change from 2001		2001		2005	% change from 2001
Characteristic	%	(95% CI [†])	%	(95% CI)	to 2005	%	(95% CI)	%	(95% CI)	to 2005
Age group (yrs)										
18–24	60.5	(58.5-62.5)	62.0	(59.9-64.0)	2.5	50.6	(48.8 - 52.3)	52.7	(51.0-54.4)	4.2
25-34	51.4	(50.0-52.9)	51.5	(50.1–52.9)	0.2	47.7	(46.6–48.8)	50.5	(49.4–51.6)	5.9 [§]
35–44	47.8	(46.5–49.1)	49.6	(48.4–50.8)	3.8	46.2	(45.0–47.3)	49.7	(48.8–50.6)	7.6 [§]
45-64	43.3	(42.3–44.4)	46.5	(45.6–47.3)	7.4 [§]	40.6	(39.8–41.5)	45.5	(44.8–46.2)	12.1 [§]
<u>></u> 65	43.1	(41.6–44.6)	44.5	(43.4–45.6)	3.3	32.2	(31.2–33.2)	36.3	(35.5–37.1)	12.7 [§]
Race/Ethnicity										
White, non-Hispanic	50.6	(50.0-51.2)	52.3	(51.8-52.9)	3.4§	46.0	(45.5-46.6)	49.6	(49.2-50.1)	7.8§
Black, non-Hispanic	40.3	(38.3–42.4)	45.3	(43.3–47.3)	12.4§	31.4	(30.0–32.9)	36.1	(34.8–37.5)	15.0§
Hispanic	42.0	(39.4–44.6)	41.9	(39.8–44.0)	-0.2	36.3	(34.5–38.1)	40.5	(38.8–42.1)	11.6 [§]
Other race	43.1	(40.5–45.8)	45.7	(43.4–48.1)	6.0	41.2	(38.6–43.8)	46.6	(44.4–48.9)	13.1 [§]
Education level										
Less than high school										
graduate	35.8	(33.9 - 37.9)	37.2	(35.4 - 39.0)	3.9	34.2	(32.5 - 35.9)	37.1	(35.5 - 38.7)	8.5 [§]
High school graduate	46.0	(44.9–47.1)	47.9	(46.9–48.9)	4.1 [§]	40.3	(39.5–41.2)	43.2	(42.4-44.0)	7.2§
Some college	50.3	(49.1–51.4)	50.3	(49.2–51.4)	0.0	44.3	(43.4–45.2)	47.9	(47.2–48.7)	8.1 [§]
College graduate	52.6	(51.5–53.7)	54.6	(53.6–55.6)	3.8§	49.1	(48.1–50.1)	53.3	(52.5–54.1)	8.6 [§]
Total	48.0	(47.3–48.6)	49.7	(49.2–50.3)	3.5 [§]	43.0	(42.5–43.5)	46.7	(46.2–47.1)	8.6 [§]

^{*} At least 30 minutes a day of moderate-intensity activity on 5 or more days a week, or at least 20 minutes a day of vigorous-intensity activity on 3 or more _days a week, or both.

of women reported engaging in regular physical activity, with the largest increases reported among non-Hispanic black women and men. However, among racial/ethnic groups in 2005, only non-Hispanic white men (52.3%) had reached the *Healthy People 2010* target of 50% of adults engaging in regular physical activity, although non-Hispanic white women (49.6%) had nearly reached that target.

The findings in this report are consistent with previous BRFSS physical-activity analyses (5), including a decrease in leisure-time physical inactivity from 2001 to 2004 among men and women in all racial/ethnic groups (6). These BRFSS findings and those from the previous BRFSS reports suggest that U.S. adults are becoming more physically active. However, data from the National Health Interview Survey indicate that regular leisure-time physical activity among U.S. adults decreased among men and did not change significantly among women from 2000 and 2005 (7). Differences in format, period of recall, and activities assessed might explain the differences in results from the two surveys.

In addition to the racial/ethnic disparities, disparities in education also were observed. In 2001 and 2005, increasing education level was associated with increased prevalence of regular physical activity in both men and women. In

2005, 54.6% of men and 53.3% of women who were college graduates engaged in regular physical activity, compared with 37.2% of men and 37.1% of women with less than a high school education. Why persons with higher levels of education reported more physical activity is not clear.

The findings in this report are subject to at least four limitations. First, BRFSS data are self-reported and subject to recall bias. Second, the survey questions were not designed to assess whether a combination of moderate and vigorous physical activity met the requirement for engaging in regular physical activity when the two activity types measured separately did not; therefore, prevalences might have been underestimated. Third, the "other race" category combined multiple racial and ethnic groups. Although this approach increased the power of analysis by creating a larger group, analysis could not be extended to any individual groups included in this category. Finally, persons without landline telephones are not eligible for participation in the BRFSS and might be younger or of lower socioeconomic status (8); their exclusion might affect estimates of regular physical activity.

In 2005, fewer than half the adult U.S. population engaged in recommended levels of physical activity. To increase physical-activity levels in the United States, CDC

Confidence interval.

Statistically significant change (p<0.05 by t-test).</p>

encourages states to implement evidence-based intervention strategies such as those described in the *Guide to Community Preventive Services*. Examples of recommended intervention strategies include communitywide campaigns, point-of-decision prompts, social support for physical activity, and enhanced access to places to be physically active combined with informational outreach. Certain communities have successfully implemented these strategies to increase physical-activity levels. For example, Marin County, California developed a multipronged approach to encourage children and parents to walk or bike to schools daily (9). As a result, participating schools reported an increase in trips made by walking (64%) and biking (114%).

Despite increases in prevalence of physical activity among minorities, racial/ethnic disparities persist. Many persons in racial/ethnic minority groups are at increased risk for heart disease, hypertension, and diabetes, all of which have been linked to low levels of physical activity (10). To help eliminate racial and ethnic disparities in health, CDC implemented REACH Across the United States (REACH US) as a national, multilevel program. REACH US communities have implemented culturally appropriate, community-based, physical-activity interventions, including free classes, walking clubs, and faith-based nutrition and activity programs. State and local public health agencies should consult the Community Guide to Preventive Services and successful REACH US communities for examples of culturally appropriate, evidence-based initiatives to further increase physical-activity levels among racial and ethnic minorities.

References

- US Department of Health and Human Services. Physical activity and health: report of the Surgeon General. Atlanta, GA: US Department of Health and Human Services, CDC; 1996.
- 2. Pate RR, Pratt M, Blair SN, et al. Physical activity and public health: a recommendation from the Centers for Disease Control and Prevention and the American College of Sports Medicine. JAMA 1995:273:402–7
- 3. CDC. DATA2010: the Healthy People 2010 database. Available at http://wonder.cdc.gov/data2010.
- 4. CDC. 2001 and 2005 BRFSS summary data quality reports. Atlanta, GA: US Department of Health and Human Services, CDC; 2002 and 2006. Available at http://ftp.cdc.gov/pub/data/brfss/2001summarydataqualityreport.pdf and http://ftp.cdc.gov/pub/data/brfss/2005summarydataqualityreport.pdf.
- CDC. Prevalence of physical activity, including lifestyle activities among adults—United States, 2000–2001. MMWR 2003;52:764–9.
- CDC. Trends in leisure-time physical inactivity by age, sex, and race/ ethnicity—United States, 1994–2004. MMWR 2005;54:991–4.
- 7. Barnes P. Physical activity among adults: United States, 2000 and 2005. Hyattsville, MD: US Department of Health and Human Services, CDC; 2007. Available at http://www.cdc.gov/nchs/products/pubs/pubd/hestats/physicalactivity/physicalactivity.htm.
- § Available at http://www.thecommunityguide.org/pa.

- 8. Blumberg SJ, Luke JV. Wireless substitution: early release of estimates based on data from the National Health Interview Survey, July—December 2006. Hyattsville, MD: US Department of Health and Human Services, CDC; 2007. Available at http://www.cdc.gov/nchs/nhis.htm.
- Staunton CE, Hubsmith D, Kallins W. Promoting safe walking and biking to school: the Marin County success story. Am J Pub Health 2003;93:1431–4.
- 10. The Office of Minority Health. Data/statistics. Hyattsville, MD: US Department of Health and Human Services, The Office of Minority Health. Available at http://www.omhrc.gov/templates/browse.aspx?lvl=1&lvlid=2.

Norovirus Outbreak Associated with III Food-Service Workers — Michigan, January–February 2006

On January 30, 2006, the Barry-Eaton District Health Department (BEDHD) in Michigan was notified of gastrointestinal illness in several members of two dining parties after a meal at an Eaton County restaurant on January 28. An investigation was initiated by BEDHD to identify the source and agent of infection and to determine the scope of illness among patrons and employees of this national chain restaurant. Norovirus genogroup I (GI) was detected in stool specimens submitted by multiple patrons and employees. The investigation revealed that several foodservice workers had been ill during January 19-February 3, 2006, and that a line cook had vomited in the restaurant on January 28, possibly increasing environmental contamination and transmission of virus. This report summarizes the findings of the outbreak investigation, which determined that at least 364 restaurant patrons had become ill. The findings underscore the need for 1) ongoing education of food-service workers regarding prevention of norovirus contamination and transmission; 2) enforcement of policies regarding ill and recently ill food-service workers; and 3) environmental decontamination with effective disinfectants to eliminate the presence of norovirus.

After learning of the outbreak on January 30, BEDHD launched an epidemiologic and environmental assessment. The restaurant was open for dinner on weekdays and lunch and dinner on weekends and served up to 800 persons daily with a staff of 32–50 employees. Initial investigation indicated that the index case was in an employee who worked as a server at the restaurant and became ill with symptoms of vomiting on or around January 19. Work records indicated that this employee did not work while ill. A second employee (a sibling to the server) became ill with abdominal cramps, diarrhea, and vomiting on January 21 and

worked on the first and second days of illness; this person's duties included bartending and administrative work. Seven patrons reported that they had eaten at the restaurant during January 21–27. On January 28, a line cook (line cook A) vomited at home (at approximately 6:00 a.m.) before reporting to work at 11:00 a.m., then vomited again into a waste bin beside the frontline workstation at approximately 2:00 p.m. while preparing antipasti platters, pizzas, and salads. After vomiting, line cook A remained on site (but off the cooking line) and left work at 4:15 p.m. This person also reported to work on January 29 from 11:00 a.m. to 4:30 p.m. while still experiencing loose stools.

BEDHD began case finding by obtaining names of patrons from credit card receipts, records of delivery and catering events, and records of dinner reservations; information on patrons without reservations or those who paid with cash was not available. Using Internet-based telephone directories, BEDHD contacted patrons who dined at or consumed food prepared by the restaurant during January 19–February 3. Many patrons contacted BEDHD as a result of the extensive media coverage. BEDHD staff members administered patron interviews by telephone; the interviews included questions about basic demographics, date and time of the restaurant meal, food history, and illness history. Restaurant employees were interviewed in person or by telephone and additionally asked about their work schedules for this period.

BEDHD conducted two studies: 1) a descriptive study to characterize ill persons and 2) an analytic study to determine whether certain foods were associated with illness. Because only a portion of restaurant patrons could be identified or contacted, a case-control methodology was used for the analytic study.

For the descriptive study, a case in a patron was defined as illness in a patron who had eaten food prepared at the restaurant during January 19–February 3 and who had become ill with vomiting or diarrhea within 10–50 hours (1) after eating the food. A case in an employee was defined as illness in an employee who was ill with vomiting or diarrhea during January 19–February 3, regardless of the incubation period. To determine whether any changes occurred in rates of illness among patrons based on the time the meal was eaten, attack rates were calculated in 3-hour intervals for January 28 and 29, by dividing the number of cases in patrons who dined during each time interval by the number of meals served for those periods.

For the analytic study, a case-patron was defined as a patron who had eaten food prepared at the restaurant during January 28–29 (the 2 days line cook A worked while symptomatic) and subsequently became ill with vomiting

or diarrhea 10–50 hours after eating; a control was a patron who had the same exposure but no gastrointestinal illness. Statistical software was used to perform the analysis. Chi-square and Fisher's exact tests were used in the case-control analysis.

Stool specimens, obtained from patrons and employees, were tested for norovirus RNA by reverse transcriptase–polymerase chain reaction (RT-PCR) and for bacterial pathogens at the Michigan Department of Community Health (MDCH). All positive RT-PCR specimens were genotyped by sequence analysis.

Descriptive Study

A total of 625 persons were interviewed by BEDHD: 584 patrons (113 were well), 32 employees, and nine additional persons who became ill after contact with a patron or employee in whom a case was identified. A total of 364 patrons of the 584 interviewed met the descriptive study case definition; the median age was 40 years (range: 1–92 years), 58.5% were female, 88.2% reported diarrhea, 71.7% reported vomiting, and the median duration of illness was 42 hours (range: 2–172 hours) (Table). Patron onset of illness peaked during 12:00 a.m.–3:59 a.m. on January 30 (Figure 1). The median time from a meal at the restaurant until onset of symptoms was 32 hours. The number of cases was already decreasing on January 30, when BEDHD was notified and interventions were implemented.


A total of 281 patrons in whom cases were identified had dined on January 28, resulting in an attack rate of 33.7%; on January 29, the attack rate was 13.5% (64 cases divided by 475 meals). Analysis of patron illness based on date and time that the meal was eaten demonstrated that norovirus transmission was occurring in the restaurant before the vomiting incident on January 28 (Figure 2). The attack rate was highest for patrons who ate during 5:00 p.m.–7:59 p.m. on January 28. Transmission continued through the next day.

TABLE. Selected characteristics of patrons (n = 364) who became ill in a norovirus outbreak associated with a restaurant—Eaton County, Michigan, January 28–February 4, 2006

Characteristic	Me	asure
Median age (yrs) (range)	40	(1–92)
No. female (%)	213	(58.5)
No. who reported diarrhea (%)	321	(88.2)
No. who reported bloody diarrhea (%)	7	(1.9)
No. who reported vomiting (%)	261	(71.7)
Median incubation period (hrs) (range)	32	(10-50)
Median duration of illness (hrs) (range)	42	(2-172)
No. who sought medical attention (%)*	30	(8.2)
No. who visited a hospital emergency department (%)	6	(1.6)

^{*} Includes persons who visited a hospital emergency department.

FIGURE 1. Number of cases of norovirus illness among patrons and employees* of a restaurant,† by 4-hour time interval§ of illness onset — Eaton County, Michigan, January 28–February 4, 2006




Month, day, and 4-hour time interval of illness onset

The first two employees in whom cases were identified (onset dates January 19 and 21) and the strict two patrons in whom cases were identified (onset dates January 23) are not included.

⁸Time intervals: 1) 12:00 a.m. to 3:59 a.m.; 2) 4:00 a.m. to 7:59 a.m.; 3) 8:00 a.m. to 11:59 a.m.; 4) ₈ 12:00 p.m. to 3:59 p.m.; 5) 4:00 p.m. to 7:59 p.m.; and 6) 8:00 p.m. to 11:59 p.m.

Cases in persons who had not eaten at the restaurant but became ill after contact with a patron or employee in whom a case was identified.

FIGURE 2. Attack rate among patrons* who ate at a restaurant implicated in a norovirus outbreak, by 3-hour time interval of eating a meal at the restaurant — Eaton County, Michigan, January 28 and January 29, 2006



*N = 345. Attack rate calculated by dividing the number of cases in patrons by number of meals served.

Of the 32 employees interviewed, cases were identified in 17 (53.1%). Seven (41.2%) of these 17 employees had worked while ill during January 21–30. Twelve employees (other than line cook A) worked on January 28 and subsequently became ill. Five (62.5%) of the eight line cooks who worked on January 28 became ill on or after January 28, compared with six (28.6%) of 21 servers.

Analytic Study

In the case-control study of patrons from the period January 28-29, a total of 45 were classified as casepatrons, and 91 were classified as controls. Two foods were found to have a statistically significant association with illness: the antipasti platter (odds ratio [OR] = 2.96; 95% confidence interval [CI] = 1.08-8.14) and garlic mashed potatoes (OR = 4.05; CI = 1.37-11.99). Eighteen patrons (10 who were ill and eight who were well) reported eating the antipasti platter. Sixteen patrons (10 ill and six well) reported eating the garlic mashed potatoes.

Nine persons who had not eaten or worked at the restaurant became ill after contact with either a case-patron

or case-employee (i.e., household or work contacts). Eight of these nine persons had symptoms of vomiting or diarrhea with illness onset during January 30–February 7.

All 14 stool specimens tested by RT-PCR were positive for norovirus GI. The companion bacterial samples tested negative. Results from the sequence analysis, using the degenerative primer set to produce a 213-bp amplicon of region B of the norovirus genome, demonstrated 100% sequence homology with the genotype GI/4 Chiba.

Environmental Assessment

The BEDHD environmental assessment of the restaurant identified deficiencies with employee hand-washing practices, cleaning and sanitizing of food and nonfood contact surfaces, temperature monitoring and maintenance of potentially hazardous food, and maintenance of hand-sink stations for easy accessibility and proper use. Three

^{*} Cases among patrons defined as illness with vomiting or diarrhea, with an incubation period of 10–50 hours. Cases among employees defined as illness with vomiting or diarrhea during January 19–, February 3, regardless of incubation period.

interventions were undertaken by the restaurant beginning January 30: 1) all food prepared during January 27-30 was discarded; 2) all ill employees were excluded from working for at least 72 hours after their symptoms had subsided; and 3) the facility was cleaned extensively. On February 3, BEDHD received reports of illness in three patrons who had dined at the restaurant on February 1, raising concern that residual contamination remained. Also on February 3, while reviewing the restaurant's clean-up procedures after the vomiting incident, BEDHD sanitarians discovered the restaurant had used a quaternary ammonium-based sanitizer that was ineffective against norovirus. BEDHD instructed the restaurant to disinfect according to MDCH and Michigan Department of Agriculture guidelines for environmental cleaning and disinfection of norovirus (2). The restaurant completed the disinfection with bleach solution before opening at 4:00 p.m. on February 3.

Reported by: SR Bohm, MS, BM Brennan, MSPH, Michigan Dept of Community Health; R Schirmer, MD, G Cabose, Barry-Eaton District Health Dept, Charlotte, Michigan.

Editorial Note: Norovirus can be transmitted person-toperson (via the fecal-oral route) and spread through contaminated airborne droplets, food, water, environmental surfaces, and fomites (3). In the outbreak described in this report, at least 364 restaurant patrons became ill with gastroenteritis after dining at a restaurant where employees had reported to work while ill. In a norovirus outbreak, a vomiting incident is a major risk factor for norovirus illness and can double the attack rate (4). In this outbreak, vomiting by a line cook at the work station might have contributed to transmission. Because of the open physical layout of the restaurant, no barrier impeded airborne spread of the virus from the kitchen to the main dining area. Attack rates increased after this incident, and among employees who worked on January 28, a higher percentage of line cooks became ill compared with servers. In addition, other environmental contamination probably contributed to transmission. Low-level transmission was occurring in the week before January 28; seven patrons who dined at the restaurant during January 21-27 met the case definition. During January 21-February 3, exposure to virus likely occurred by contact with contaminated surfaces and objects.

Foodborne transmission also might have contributed to the outbreak. The antipasti platter (a combination of calamari, bruschetta, and mozzarella cheese sticks with marinara sauce) was one of many dishes that line cook A prepared but the only item among those line cook A prepared that had a statistically significant association with

illness. The other food that was linked with illness was the garlic mashed potatoes. However, only a small proportion of patrons ate either of these items.

Feline calicivirus, a proxy virus used for norovirus research, can persist in the environment for 21–28 days and is resistant to inactivation by certain cleaning agents (e.g., quaternary ammonium-based sanitizers) (5). In this outbreak, the restaurant's use of cleaning cloths soaked with a quaternary ammonium-based cleaning product likely was ineffective in disinfecting the restaurant (6).*

In 2006, MDCH received 144 reports of suspected or confirmed norovirus outbreaks throughout Michigan, compared with 34 in 2005 (MDCH, unpublished data, 2007). Norovirus genogroup II (GII) was identified in 97% of the 89 confirmed outbreaks in the state during 2006; GI was identified in the remaining 3% of the outbreaks. During 2000–2004, the predominant genogroup in calicivirus outbreaks in the United States was GII (79%), followed by GI (19%) and sapovirus (2%) (7). No other GI/4 outbreaks were detected in Michigan in 2006. In this outbreak, the detection of one norovirus genogroup (GI/4) in all stool specimens, including that of line cook A, suggests a single source of infection.

Approximately 50% of all norovirus outbreaks are linked to ill food-service workers (8). The Michigan Food Law of 2000, which regulates Michigan food establishments, requires that food-establishment operators notify regulators when employees have infections with Salmonella, Shigella, Escherichia coli O157:H7 or hepatitis A. Food-service employees in Michigan also are obliged under the food law to inform their supervisors when they have symptoms of illness, such as diarrhea and vomiting. In October 2007, Michigan adopted several amendments to the Michigan Food Law of 2000, including the 2005 Food and Drug Administration Food Code. The 2005 Food Code includes norovirus as one of several highly pathogenic organisms that can be easily spread by ill food handlers and provides disease-specific conditions for work exclusion, restriction, and reinstatement.

After the outbreak described in this report, BEDHD issued four recommendations (based on previously

^{*}The Environmental Protection Agency has approved the claims of effectiveness against norovirus of several antimicrobial disinfectants. Some of these products include quaternary ammonia-based disinfectants but are in combination with alcohols. These claims of effectiveness are based on in vitro studies that typically use a proxy virus (e.g., feline calicivirus); field effectiveness in the context of outbreaks has not been evaluated. A list of these products is available at http://www.epa.gov/oppad001/list_g_norovirus.pdf.

[†] Available at http://www.michigan.gov/mda/1,1607,7-125-1568_2387_2435---.00.html.

[§] Available at http://www.cfsan.fda.gov/~dms/fc05-toc.html.

published guidelines [9]) for infection control and environmental decontamination after any vomiting incident in a food-service establishment. First, any exposed food or single-service articles (e.g., drinking straws, takeout containers, and paper napkins) should be discarded, and all surface areas within at least a 25-foot radius of the vomiting site should be disinfected with a bleach solution (2). Second, ill employees should be excluded from work for at least 72 hours after symptoms subside, and employees returning after a gastrointestinal illness should be restricted from handling kitchenware or ready-to-eat food for an additional 72 hours. Third, because thorough disinfection might be necessary, partial or complete closure of the food establishment should be considered after a vomiting incident. Finally, restrooms used during or after a vomiting incident should be closed immediately until they are disinfected properly with bleach solution.

Acknowledgments

This report is based, in part, on contributions by the Barry-Eaton District Health Dept; E Belk, P Clark, V Leykam, L Mosher, J Massey, S Bidol, J Collins, S Johnson, C Miller, MG Stobierski, M Wilkins, A Mattson, Michigan Dept of Community Health; and L Hainstock, Michigan Dept of Agriculture.

References

- Heymann DL (ed). Control of communicable diseases manual. 18th edition. Washington, DC: American Public Health Association; 2004:227–9.
- Michigan Department of Community Health, Michigan Department of Agriculture. Local health department guidelines for environmental cleaning and disinfection of norovirus. Available at http://www.michigan.gov/ documents/Guidelines_for_Environmental_Cleaning_125846_7.pdf.
- CDC. Norwalk-like viruses. Public health consequences and outbreak management. MMWR 2001;50(No. RR-9):1–17.
- Marks PJ, Vipond IB, Regan FM, Wedgwood K, Fey RE, Caul EO. A school outbreak of Norwalk-like virus: evidence for airborne transmission. Epidemiol Infect 2003;131:727–36.
- Doultree JC, Druce JD, Birch CJ, Bowden DS, Marshall JA. Inactivation of feline calicivirus, a Norwalk virus surrogate. J Hosp Infect 1999;41:51–7.
- Barker J, Vipond IB, Bloomfield SF. Effects of cleaning and disinfection in reducing the spread of norovirus contamination via environmental surfaces. J Hosp Infect 2004;58:42–9.
- 7. Blanton LH, Adams SM, Beard RS, et al. Molecular and epidemiologic trends of caliciviruses associated with outbreaks of acute gastroenteritis in the United States, 2000–2004. J Infect Dis 2006;193:413–21.
- Widdowson M-A, Sulka A, Bulens S, et al. Norovirus and foodborne disease, United States, 1991–2000. Emerg Infect Dis 2005;11:95–102.
- Southern Nevada Health District. Guidelines for the prevention and control of norovirus in hotel/casinos. Available at http:// www.southernnevadahealthdistrict.org/download/fact_sheets/ norovirus_recommendations.pdf.

Notice to Readers

National Influenza Vaccination Week — November 26–December 2, 2007

To help raise awareness regarding the importance of obtaining influenza vaccination throughout the entire influenza season, the U.S. Department of Health and Human Services, National Influenza Vaccine Summit, CDC, and other partners are conducting activities during the second annual National Influenza Vaccination Week (NIVW), November 26–December 2.

Influenza vaccination coverage in all groups recommended for vaccination remains suboptimal. Despite the timing of the peak of influenza disease, administration of vaccine decreases substantially after November. According to results from the National Health Interview Survey regarding the two most recent influenza seasons, approximately 84% of all influenza vaccinations were administered during September-November* (Figure). Among persons aged ≥65 years, the percentage of September-November vaccinations was even higher, at 92% (CDC, unpublished data, 2007). Because many persons recommended for vaccination remain unvaccinated at the end of November, CDC is encouraging public-health partners and health-care providers to conduct vaccination clinics and other activities that promote influenza vaccination during NIVW and throughout the remainder of the influenza season.


Each year, on average, approximately 15–60 million persons in the United States are infected with influenza virus; an estimated 200,000 persons are hospitalized from influenza complications, and an estimated 36,000 persons die from those complications (1). Influenza vaccination is the best way to prevent influenza and potentially severe complications. CDC recommends that anyone who wants to reduce their risk for influenza infection should be vaccinated every influenza season. Annual vaccination is particularly important for the following groups (1).

- persons at high risk for influenza-related complications and severe disease, including:
 - children aged 6-59 months,
 - pregnant women,

^{*} Respondents were asked two series of questions: "During the past 12 months, have you had a flu shot?" "A flu shot is usually given in the fall and protects against influenza for the flu season." "During what month and year did you receive your most recent flu shot?" and "During the past 12 months, have you had a flu vaccine sprayed in your nose by a doctor or other health professional?" "A health professional may have let you spray it." "This vaccine is usually given in the fall and protects against influenza for the flu season." "During what month and year did you receive your most recent flu nasal spray?" Additional information is available at http://www.cdc.gov/nchs/nhis.htm.

- persons aged ≥50 years,
- persons of any age with certain chronic medical conditions; and
- persons who live with or care for persons at high risk, including:
 - household contacts and caregivers of persons in the above groups,
 - household contacts and caregivers of children aged <6 months (these children also are at high risk for influenza-related complications but are too young to receive influenza vaccination), and
 - health-care workers.

FIGURE. Estimated number of persons reporting vaccination* for influenza, by month — National Health Interview Survey, United States, 2005–06 and 2006–07 influenza seasons



- *Respondents were asked two series of questions: "During the past 12 months, have you had a flu shot?" "A flu shot is usually given in the fall and protects against influenza for the flu season." "During what month and year did you receive your most recent flu shot?" and "During the past 12 months, have you had a flu vaccine sprayed in your nose by a doctor or other health professional?" "A health professional may have let you spray it." "This vaccine is usually given in the fall and protects against influenza for the flu season." "During what month and year did you receive your most recent flu nasal spray?"
- Estimates are based on 1-month sampling weights.

§ Persons aged ≥6 months for whom month of influenza vaccination was reported in interviews conducted in March 2007.

¶reported in interviews conducted in March 2007.

Persons aged ≥6 months for whom month of influenza vaccination was reported in interviews conducted in March 2006.

SOURCE: 2006 National Health Interview Survey final data and 2007 National Health Interview Survey preliminary data. Estimates for the 2006–07 influenza season might change as more data become available. Estimates are based on household interviews of the civilian noninstitutionalized population. Additional information available at http://www.cdc.gov/nchs/nhis.htm.

The time to receive influenza vaccination starts when vaccine becomes available in the local community and continues into January or later, when the influenza season typically peaks. Throughout NIVW, CDC will be highlighting the importance of influenza vaccination for persons at high risk, their close contacts, and all those who want to be protected from influenza. CDC, Families Fighting Flu, and other partners also have designated Tuesday, November 27, as Children's Flu Vaccination Day to put a special focus on the importance of vaccinating children at high risk and their close contacts.

NIVW posters and other influenza educational materials are available to download for local printing and distribution at http://www.cdc.gov/flu/professionals/flugallery. Other influenza-related tools and information for healthcare professionals and patients are available at http://www.cdc.gov/flu.

Reference

 CDC. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2007;56(No. RR-6).

Notice to Readers

Expansion of Use of Live Attenuated Influenza Vaccine (FluMist®) to Children Aged 2–4 Years and Other FluMist Changes for the 2007–08 Influenza Season

On September 19, 2007, MedImmune Vaccines (Gaithersburg, Maryland) received approval from the Food and Drug Administration (FDA) to expand the use of FluMist[®], a live, attenuated influenza vaccine (LAIV), to children aged 2-4 years (i.e., 24-49 months). FluMist is an intranasally administered influenza vaccine that was first licensed by the FDA in 2003 for healthy, nonpregnant persons aged 5-49 years (1). Expanding the age indications to include healthy children aged 2-4 years provides another influenza vaccination option for young children. In granting the new approval, FDA emphasized that FluMist is not approved for vaccination of children aged <2 years or adults aged >49 years, and that FluMist safety has not been established in persons with underlying medical conditions predisposing them to influenza-related complications (2). In addition, FluMist should not be administered to persons with asthma or children aged <5 years with recurrent wheezing (1,2).

New Recommendation for FluMist

In a randomized trial published in 2007, FluMist and trivalent inactivated vaccine (TIV) were compared among children aged 6–59 months (3). Children with medically diagnosed or treated wheezing within 42 days before enrollment, or a history of severe asthma, were excluded from this study. FluMist had a 55% (95% confidence interval [CI] = 45%–63%) greater efficacy compared with TIV in preventing culture-confirmed influenza illness.

In the trial, among children aged 6–23 months, wheezing that required bronchodilator therapy or that was associated with significant respiratory symptoms occurred in 5.9% of FluMist recipients, compared with 3.8% of those who received TIV (risk ratio [RR] = 1.5, CI = 1.2–2.1). Wheezing was not greater among children aged 24–59 months who received FluMist (3). In a previous randomized placebo-controlled safety trial among children aged 12 months–17 years, an elevated risk for asthma events (RR = 4.06, CI = 1.29–17.86) was noted among 728 children aged 18–35 months who received FluMist; of the 16 children with asthma-related events, none required hospitalization, and elevated risks for asthma were not observed in other age groups (4).

During 2006-2007, the Advisory Committee on Immunization Practices (ACIP) influenza vaccine workgroup reviewed data on the use of FluMist among children aged 2-4 years. On the basis of these data, expert opinion of the workgroup members, and consultation with representatives from the American Academy of Pediatrics and immunization safety experts, the workgroup revised recommendations for use of LAIV to include children aged 2-4 years, and presented its recommendations to ACIP. On October 24, 2007, ACIP recommended that either LAIV or TIV can be used to vaccinate healthy nonpregnant persons aged 2-49 years. For the purposes of this recommendation, healthy persons were defined as persons who do not have an underlying medical condition that predisposes them to influenza complications (5). ACIP also approved use of FluMist for healthy persons aged 2-18 years under the federal Vaccines for Children (VFC) program.

Although FDA licensure of FluMist excluded children aged 2–4 years with a history of asthma or recurrent wheezing, the precise risk, if any, of wheezing caused by FluMist among these children is unknown because experience with FluMist among these young children is limited. Young children might not have a history of recurrent wheezing if their exposure to respiratory viruses has been limited because of their age. Certain children might have a history of wheezing with respiratory illnesses but have not had

asthma diagnosed. The ACIP influenza vaccine workgroup, with advice from consultants, developed the following screening recommendations to assist persons who administer influenza vaccines in providing the appropriate vaccine for children aged 2–4 years.

Clinicians and immunization programs should screen for possible reactive airways diseases when considering use of FluMist for children aged 2-4 years, and should avoid use of this vaccine in children with asthma or a recent wheezing episode. Health-care providers should consult the medical record, when available, to identify children aged 2-4 years with asthma or recurrent wheezing that might indicate asthma. In addition, to identify children who might be at greater risk for asthma and possibly at increased risk for wheezing after receiving LAIV, parents or caregivers of children aged 2-4 years should be asked: "In the past 12 months, has a health-care provider ever told you that your child had wheezing or asthma?" Children whose parents or caregivers answer "yes" to this question and children who have asthma or who had a wheezing episode noted in the medical record within the past 12 months, should not receive FluMist. TIV is available for use in children with asthma or possible reactive airways diseases.

Other Changes in FluMist Use for 2007–08

Three other changes in the use of FluMist and its 2007-08 formulation should be noted; the amount of vaccine administered, the temperature at which FluMist is shipped and stored after delivery to the end-user, and the minimum interval between doses have changed compared with the 2006-07 influenza season formulation. First, FluMist is now supplied in a prefilled, single-use sprayer containing 0.2 mL of vaccine instead of the previous 0.5 mL dose. Persons administering FluMist should spray 0.1 mL (i.e., half of the total sprayer contents) into the first nostril while the recipient is in an upright position. An attached dose-divider clip should then be removed from the sprayer and the second half of the dose administered into the other nostril. Second, FluMist is now approved to be shipped to end users at 35°F-46°F (2°C-8°C) instead of being shipped and stored frozen. FluMist should be stored at 35°F-46°F (2°C-8°C) upon receipt, and can remain at that temperature until the expiration date is reached. (2) Third, the recommended interval from the first to the second dose in children requiring 2 doses has changed from a minimum of 6 weeks to a minimum of 4 weeks, the same interval recommended between doses for TIV (2).

Regardless of the vaccine used, ACIP, the American Academy of Pediatrics, and the American Academy of Family Physicians recommend that children aged <9 years who

Vol. 56 / No. 46 MMWR 1219

have not previously been administered an influenza vaccine should receive 2 doses separated by 4 or more weeks in the initial year (6). Children aged <9 years who did not receive the recommended second dose of influenza vaccine in the initial year that they received influenza vaccine should receive 2 doses separated by 4 or more weeks before or during the next influenza season. This recommendation applies only to the influenza season that follows the first season that a child aged <9 years receives influenza vaccine (5,7). Children aged <9 years who are being vaccinated two or more seasons after receiving an influenza vaccine for the first time should receive a single annual dose, regardless of the number of doses administered previously (5,7). Additional information is available from the manufacturer's package insert (2) and MedImmune Vaccines, telephone 877-358-6478.

References

- Food and Drug Administration. FDA approves nasal influenza vaccine for use in younger children. Rockville, MD: Food and Drug Administration; 2007. Available at http://www.fda.gov/bbs/topics/news/2007/ new01705.html.
- FluMist [package insert]. Gaithersburg, MD: Medimmune Vaccines, Inc.; 2007. Available at http://www.flumist.com/pdf/flumist-prescribing-information.pdf.
- Belshe RB, Edwards KM, Vesikari T, et al. Live attenuated versus inactivated influenza vaccine in infants and young children. N Engl J Med 2007;356:685–96.
- Bergen R, Black S, Shinefield H, et al. Safety of cold-adapted live attenuated influenza vaccine in a large cohort of children and adolescents. Pediatr Infect Dis J 2004;23:138

 –44.
- CDC. Prevention and control of influenza: Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2007. MMWR 2007;56(No. RR-6).
- CDC. Recommended immunization schedules for persons aged 0–18 years—United States, 2007. MMWR 2007;55(51&52):Q1–Q4.
- 7. American Academy of Pediatrics Committee on Infectious Diseases. Prevention of influenza: recommendations for influenza immunization of children, 2006–2007. Pediatrics 2007;119:846–51.

Notice to Readers

Availability of Additional Trivalent Inactivated Influenza Vaccine for Adults (Afluria®)

On September 28, 2007, CSL Biotherapies, Inc., (King of Prussia, Pennsylvania) received approval from the Food and Drug Administration for use of Afluria[®], a trivalent inactivated influenza vaccine (TIV) administered intramuscularly in persons aged \geq 18 years (*1*). Afluria can be used for any adult influenza vaccine indication (*2*).

The addition of Afluria brings to six (five TIVs and one live, attenuated influenza vaccine) the number of seasonal influenza vaccines licensed for the U.S. market. CDC

estimates that manufacturers of the six vaccines will supply a record 132 million doses of influenza vaccine for the 2007–08 influenza season.

Afluria is available in a 0.5 mL preservative-free, single-dose, prefilled syringe and in a 5 mL multidose vial containing 10 doses. Thimerosal, a mercury derivative, is added as a preservative to the multidose vial; each 0.5 mL dose contains 24.5 μ g of mercury. Additional information is available from the manufacturer's package insert (*3*) and CSL Biotherapies, Inc., telephone 888-435-8633.

References

- Food and Drug Administration. Additional influenza vaccine approved for upcoming influenza season: approval increases available doses to record level. Rockville, MD: Food and Drug Administration; 2007. Available at http://www.fda.gov/bbs/topics/news/2007/new01714.html.
- CDC. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2007. MMWR 2007;56(No. RR-6).
- 3. Afluria [package insert]. King of Prussia, PA: CSL Biotherapies, Inc.; 2007. Available at http://www.afluria.com/pi.pdf.

Notice to Readers

Satellite Broadcast: Surveillance of Vaccine-Preventable Diseases 2007

On December 13, 2007, CDC and the Public Health Training Network will present the satellite broadcast and webcast, Surveillance of Vaccine-Preventable Diseases 2007. The 3.5-hour broadcast will occur live from 9:00 a.m. to 12:30 p.m. EST. This program is designed to provide information on case investigation, outbreak control, and disease reporting for vaccine-preventable diseases, and will discuss methods of enhancing surveillance and completing case investigations. The program is specifically targeted to persons with surveillance responsibilities (e.g., those in state health departments). The broadcast will feature a live question-and-answer session in which participants nationwide can interact with course instructors via toll-free telephone lines. Continuing education credits will be provided. Additional information about the program is available at http://www2a.cdc.gov/phtn/vpd-07.

Information for site administrators about establishing and registering a viewing location is available at http://www.cdc.gov/tceonline. No registration is necessary to access the webcasts via an Internet connection. The link to the live webcast is available at http://www2a.cdc.gov/phtn/webcast/vpd-07. The webcast will be accessible through an Internet connection until January 14, 2008. The program will become available as a self-study DVD and Internet-based program in January 2008.

TABLE I. Provisional cases of infrequently reported notifiable diseases (<1,000 cases reported during the preceding year) — United States, week ending November 17, 2007 (46th Week)*

	Current	Cum	5-year weekly	Total	cases rep	orted for	previous	syears	
Disease	week	2007	average†	2006	2005	2004	2003	2002	States reporting cases during current week (No.
Anthrax	_	_		1	_	_	_	2	
Botulism:									
foodborne	1	18	1	20	19	16	20	28	NC (1)
infant	1	73	2	97	85	87	76	69	TN (1)
other (wound & unspecified)	_	19	0	48	31	30	33	21	()
Brucellosis	_	106	2	121	120	114	104	125	
Chancroid	_	27	1	33	17	30	54	67	
Cholera	_	6	0	9	8	5	2	2	
Cyclosporiasis§	_	88	1	136	543	171	75	156	
Diphtheria	_	_		_	_		1	1	
Domestic arboviral diseases ^{§,¶} :									
California serogroup	_	28	1	67	80	112	108	164	
eastern equine		4	0	8	21	6	14	104	
•					1	1			
Powassan	_	1	0	1			41	1	
St. Louis	_	5		10	13	12	41	28	
western equine	_	_	_	_	_	_	_	_	
Ehrlichiosis [§] :	4	440	^	0.40	700	507	000	E44	NIV (O) MNI (O)
human granulocytic	4	443	9	646	786	537	362	511	NY (2), MN (2)
human monocytic	9	571	7	578	506	338	321	216	NY (1), MN (7), NC (1)
human (other & unspecified)	1	141	1	231	112	59	44	23	NY (1)
Haemophilus influenzae,**									
invasive disease (age <5 yrs):									
serotype b	_	16	0	29	9	19	32	34	
nonserotype b	_	123	2	175	135	135	117	144	
unknown serotype	1	180	3	179	217	177	227	153	GA (1)
Hansen disease§	1	46	2	66	87	105	95	96	IN (1)
Hantavirus pulmonary syndrome§	_	23	0	40	26	24	26	19	
Hemolytic uremic syndrome, postdiarrheal§	6	195	4	288	221	200	178	216	MI (1), ND (2), TN (1), CA (2)
Hepatitis C viral, acute	5	591	19	802	652	713	1,102	1,835	MI (2), TN (1), CA (2)
HIV infection, pediatric (age <13 yrs) ^{††}	_	_	5	52	380	436	504	420	
Influenza-associated pediatric mortality ^{§,§§}	_	75	0	43	45	_	N	N	
Listeriosis	7	599	15	875	896	753	696	665	ME (1), NY (1), MI (2), WA (2), CA (1)
Measles ^{¶¶}	_	28	1	55	66	37	56	44	
Meningococcal disease, invasive***:									
A, C, Y, & W-135	_	243	4	318	297	_	_	_	
serogroup B	2	116	2	193	156	_	_	_	OH (1), IN (1)
other serogroup	1	27	0	32	27	_	_	_	MI (1)
unknown serogroup	4	511	12	651	765	_	_	_	NY (1), FL (1), MS (1), CA (1)
Mumps	3	655	14	6,584	314	258	231	270	MI (1), NC (1), UT (1)
Novel influenza A virus infections	_	4	_	0,504 N	N	230 N	N	N	WII (1), NO (1), O1 (1)
Plague	_	6	0	17	8	3	1	2	
	_	O	_			_		_	
Poliomyelitis, paralytic		_	_	 N	1 N	N	N	N	
Poliovirus infection, nonparalytic§	_								
Psittacosis§	_	8	0	21	16	12	12	18	TN (4) TV (4)
Q fever§	2	152	1	169	136	70	71	61	TN (1), TX (1)
Rabies, human	_	_	0	3	2	7	2	3	
Rubella ^{†††}	_	11	_	11	11	10	7	18	
Rubella, congenital syndrome	_	_	_	1	1	_	1	1	
SARS-CoV ^{§,§§§}	_	_	_	_	_	_	8	N	
Smallpox§	_	_	_			-			
Streptococcal toxic-shock syndrome§	2	87	1	125	129	132	161	118	CT (1), OH (1)
Syphilis, congenital (age <1 yr)	3	402	8	380	329	353	413	412	PA (1), NC (1), LA (1)
Tetanus	1	19	0	41	27	34	20	25	FL(1)
Toxic-shock syndrome (staphylococcal)§	_	69	2	101	90	95	133	109	
Trichinellosis	_	6	0	15	16	5	6	14	
Tularemia	2	109	2	95	154	134	129	90	NE (1), AR (1)
Typhoid fever	1	298	5	353	324	322	356	321	NY (1)
Vancomycin-intermediate Staphylococcus aure		19	0	6	2	_	N	N	· /
Vancomycin-resistant <i>Staphylococcus aureus</i> §	_	_	_	1	3	1	N	N	
Vibriosis (noncholera <i>Vibrio</i> species infections)	∮ 10	317	2	Ň	N	N	N	N	GA (2), FL (3), AL (1), AZ (1), WA (1), CA (2)
Yellow fever		0.,	_			_	_	1	(-), (-), (-), (-), (-), (-)

Updated weekly from reports to the Influenza Division, National Center for Immunization and Respiratory Diseases. No cases occurring during the 2007–08 influenza season have been reported. A total of 73 cases were reported for the 2006–07 influenza season.

No measles cases were reported for the current week.

Data for meningococcal disease (all serogroups) are available in Table II.

No rubella cases were reported for the current week.

Updated weekly from reports to the Division of Viral and Rickettsial Diseases, National Center for Zoonotic, Vector-Borne, and Enteric Diseases.

TABLE II. Provisional cases of selected notifiable diseases, United States, weeks ending November 17, 2007, and November 18, 2006 (46th Week)*

(46th Week)*			Obles	:_+			0	latate or	! .			•		11-	
		Pres	Chlamyd vious	ia [⊤]				ioidomyo vious	cosis				otosporid /ious	iosis	
	Current	52 v	reeks	Cum	Cum	Current	52 v	veeks	Cum	Cum	Current	52 w	eeks	Cum	Cum
Reporting area United States	7,638	Med 20,507	Max 25,327	2007 897,828	2006 907,035	week 91	Med 139	Max 658	2007 6,529	2006 7,066	week 60	Med 83	Max 974	2007	2006 5,089
New England Connecticut Maine [§] Massachusetts New Hampshire Rhode Island [§]	7,036 1,013 201 — 678 39 71	698 217 50 301 38 62	1,357 829 74 480 73 106	31,113 9,304 2,168 14,271 1,848 2,748	29,851 8,609 2,006 13,585 1,775 2,829	N — —	0 0 0 0 0	1 0 0 0 1	2 N — 2	7,066 N — —	1 - 1 - -	5 0 1 2 1	39 39 6 11 5	9,568 290 39 48 107 50 9	351 38 40 169 44 14
Vermont§	24	19	45	774	1,047	N	0	0	N	N	=	1	3	37	46
Mid. Atlantic New Jersey New York (Upstate) New York City Pennsylvania	981 735 246	2,766 391 519 973 754	4,284 528 2,758 1,982 1,760	124,404 17,382 24,236 43,029 39,757	110,927 18,054 21,263 36,804 34,806	N N N N	0 0 0 0	0 0 0 0	N N N N	N N N N	5 -4 - 1	11 0 3 1 5	113 6 20 6 103	1,232 41 227 83 881	590 42 151 140 257
E.N. Central Illinois Indiana Michigan Ohio Wisconsin	1,819 474 — 261 1,084 —	3,194 987 399 709 754 367	6,216 1,370 646 1,059 3,641 443	148,026 43,531 17,988 31,062 39,423 16,022	150,384 47,717 17,550 31,391 35,510 18,216	1 — — 1 N	1 0 0 0 0	3 0 0 3 1 0	31 — 20 11 N	40 — 34 6 N	6 1 2 3	19 2 2 3 5	131 13 12 11 61 59	1,590 149 95 168 535 643	1,251 187 90 132 333 509
W.N. Central lowa Kansas Minnesota Missouri Nebraska [§] North Dakota South Dakota	465 140 — 279 — 46	1,211 162 156 251 459 95 27 49	1,465 252 294 314 551 183 61 84	53,655 7,760 6,998 10,814 20,584 3,956 1,262 2,281	55,074 7,471 7,013 11,492 20,444 4,750 1,606 2,298	1 N N — 1 N N	0 0 0 0 0 0 0	54 0 0 54 1 0 0	8 N N 8 N N N	1 N N 1 N N N	14 — 8 2 4 —	13 2 1 3 2 1 0 2	123 61 16 34 13 21 11	1,470 587 145 274 135 141 24 164	812 166 77 206 181 92 9 81
S. Atlantic Delaware District of Columbia Florida Georgia Maryland [§] North Carolina South Carolina [§] Virginia [§] West Virginia	451 66 — 1 — 31 — 340 13	3,964 64 111 1,168 640 393 549 506 485 60	6,760 140 166 1,767 3,822 696 1,905 3,030 621 94	174,433 3,050 4,981 51,015 22,078 17,330 24,326 27,383 21,633 2,637	174,615 3,153 2,846 43,896 31,837 18,908 29,652 20,509 21,233 2,581		0 0 0 0 0 0	1 0 0 0 0 1 0 0	3 N N 3 N N	4 N N 4 N N	20 — 17 1 — 1 — 1	20 0 0 11 4 1 1 1	69 4 2 35 22 2 18 14 5	1,130 20 3 615 208 29 102 78 64 11	1,084 15 14 498 257 18 90 126 57
E.S. Central Alabama [§] Kentucky Mississippi Tennessee [§]	556 — 221 — 335	1,455 364 150 399 521	2,044 577 691 959 721	64,132 14,702 7,466 17,564 24,400	67,994 20,758 7,815 16,839 22,582	N N N N	0 0 0 0	0 0 0 0	N N N N	N N N N	4 3 — 1	4 1 1 0 1	63 14 40 11 19	561 111 242 91 117	161 56 38 24 43
W.S. Central Arkansas [§] Louisiana Oklahoma Texas [§]	431 101 182 148	2,333 173 373 259 1,503	2,961 328 851 467 1,946	106,588 8,460 17,220 11,315 69,593	102,752 7,315 16,172 11,200 68,065		0 0 0 0	1 0 1 0 0	1 N 1 N N	1 N 1 N	4 2 — 2	5 0 1 1 2	41 8 4 11 29	329 32 41 115 141	376 22 85 38 231
Mountain Arizona Colorado Idahos Montanas Nevadas New Mexicos Utah Wyomings	349 59 101 51 — — 118 20	1,233 478 211 56 45 173 145 105 23	1,710 834 371 252 73 293 393 209 35	52,860 19,377 8,616 3,255 1,497 7,279 6,918 4,857 1,061	62,168 20,512 14,566 2,872 2,316 7,455 8,732 4,432 1,283	78 78 N N N — —	96 93 0 0 0 1 0	293 293 0 0 0 5 2 7	4,281 4,148 N N N 50 17 63 3	4,783 4,654 N N N 58 18 51	6 1 2 — — 1 1	7 0 2 0 1 0 1 0	580 6 26 71 7 3 8 499 8	2,845 44 204 432 63 18 99 1,933	384 28 69 35 135 12 41 16 48
Pacific Alaska California Hawaii Oregon [§] Washington	1,573 47 1,274 — 134 118	3,266 88 2,631 90 166 257	4,362 157 3,627 114 394 621	142,617 3,813 119,294 — 7,682 11,828	153,270 3,968 120,174 5,023 8,290 15,815	11 N 11 N N	41 0 41 0 0	311 0 311 0 0	2,203 N 2,203 N N N	2,237 N 2,237 N N N	_ _ _ _	1 0 0 0 1	16 2 0 0 16 0	121 3 — — 118 —	80 4 4 72
American Samoa C.N.M.I. Guam Puerto Rico U.S. Virgin Islands	U U - 43 U	0 3 124 3	32 — 207 543 7	U U 434 6,516 U	U 783 4,604 U	U - N U	0 0 0 0	0 0 0 0	U U N U	U U N U	U U N U	0 0 0 0	0 0 0 0	U - N U	U U N U

C.N.M.I.: Commonwealth of Northern Mariana Islands.
U: Unavailable. —: No reported cases. N: Not notifiable. Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum.

* Incidence data for reporting year 2007 are provisional. Data for HIV/AIDS, AIDS, and TB, when available, are displayed in Table IV, which appears quarterly. Chlamydia refers to genital infections caused by *Chlamydia trachomatis*.

Scontains data reported through the National Electronic Disease Surveillance System (NEDSS).

TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending November 17, 2007, and November 18, 2006 (46th Week)*

			Giardiasi	is				onorrhe	a		Hae	All age	es, all ser	z <i>ae</i> , invas otypes†	ive
	Current		rious eeks	Cum	Cum	Current		evious weeks	Cum	Cum	Current		vious veeks	Cum	Cum
Reporting area	week	Med	Max	2007	2006	week	Med	Max	2007	2006	week	Med	Max	2007	2006
United States	338	302	1,513	15,122	15,877	2,944	6,729	8,941	293,331	316,076	15	45	184	1,963	2,005
New England	_	25	54	1,252	1,298	188	109	259	4,945	5,017	_	3	19	160	152
Connecticut Maine§	_	6 3	18 10	313 172	276 168	54 —	42 2	204 8	1,897 104	2,041 114	_	0 0	7 4	47 13	43 18
Massachusetts New Hampshire	_	10 0	29 3	521 24	564 21	129	51 2	96 8	2,400 131	2,172 174	_	2	6 2	74 16	68 11
Rhode Island§	_	0	15	73	100	5	8	16	364	452	_	0	10	7	4
Vermont§	_	3	9	149	169	_	1	4	49	64	_	0	1	3	8
Mid. Atlantic New Jersey	31	56 6	127 11	2,578 221	3,146 429	232	714 114	1,537 159	31,918 5,056	29,703 4,893	5	10 1	27 5	395 55	417 75
New York (Úpstate)	28	23	108	1,040	1,116	152	116	1,035	6,046	5,539	1	3	15	114	132
New York City Pennsylvania	2 1	15 13	25 29	694 623	852 749	80	200 240	359 586	8,864 11,952	9,242 10,029	4	2 3	6 10	85 141	76 134
E.N. Central	17	46	80	2,172	2,538	756	1,266	2,591	60,141	62,135	1	6	15	259	333
Illinois Indiana	N	13 0	30 0	587 N	633 N	166	358 166	499 307	16,160 7,751	17,880 7,789	_ 1	2 1	6 7	76 54	101 71
Michigan	2	11	20	501	637	134	280	747	12,868	13,247		0	5	24	24
Ohio Wisconsin	15	15 7	37 20	731 353	736 532	456	340 126	1,570 206	17,763 5,599	17,011 6,208	_	2	5 2	91 14	76 61
W.N. Central	171	21	553	1,261	1,636	122	378	514	16,744	17,292	_	3	24	118	142
Iowa	_	5	23	272	268	19	39	60	1,696	1,702	_	0	1	1	2
Kansas Minnesota	163	3 0	11 514	171 176	177 479	_	45 66	86 86	1,980 2,791	1,976 2,879	_	0 1	2 17	9 56	17 74
Missouri Nebraska [§]	3 4	7 2	22 8	395 133	501 105	96	196 25	266 57	8,827 1,140	9,019 1,248	_	1 0	5 2	34 14	33 9
North Dakota	1	0	16	25	19	_	2	5	80	136	_	0	2	4	7
South Dakota	_	2	6	89	87	7	5	11	230	332	_	0	0	_	_
S. Atlantic Delaware	34	57 1	106 6	2,559 39	2,480 36	773 32	1,525 26	3,209 43	68,883 1,160	78,548 1,309	6	11 0	34 3	507 8	499 1
District of Columbia	_	0	7	34	57	_	47	71	2,024	1,619	_	0	1	3	7
Florida Georgia	24	24 10	47 42	1,145 556	1,007 586	_	482 284	717 2,068	20,825 9,165	21,511 15,976	3 1	3 2	8 7	143 107	151 101
Maryland [§] North Carolina	3	4 0	18 0	224	217	— 618	115 248	227 675	5,285 12,644	6,377 15,500	2	1	6 9	74 51	71 51
South Carolina§	2	2	8	94	98	_	202	1,361	11,456	9,528	_	1	4	43	34
Virginia [§] West Virginia	5	9	23 21	421 46	448 31	122 1	124 18	220 37	5,526 798	5,874 854	_	1 0	22 6	53 25	64 19
E.S. Central	10	10	23	489	408	203	541	812	24,813	27,732	1	2	9	109	99
Alabama§	4 N	5 0	11 0	230 N	194 N	— 78	155	242 268	6,490	9,603 2,828	1	0	3 1	23 2	20 5
Kentucky Mississippi	N N	0	0	N	N N	/8 —	57 148	310	2,937 6,705	2,828 6,635	_	0	2	9	12
Tennessee§	6	5	16	259	214	125	181	261	8,681	8,666	_	2	6	75	62
W.S. Central Arkansas§	4 1	6 2	55 13	323 105	326 128	292 71	989 79	1,200 120	44,370 3,644	45,265 3,821	_	2	34 2	88 8	77 8
Louisiana	_	1	9	89	83	167	221	384	9,981	9,736	_	0	2	6	20
Oklahoma Texas [§]	3 N	3 0	42 0	129 N	115 N	54 —	98 581	235 731	4,373 26,372	4,216 27,492	_	1 0	29 3	66 8	42 7
Mountain	29	31	68	1,577	1,532	96	246	346	10,530	13,772	1	4	12	223	186
Arizona Colorado	3 12	3 10	11 26	180 519	149 500	18 58	103 47	175 93	4,078 2,162	5,117 3,317	_	1 1	6 4	79 52	77 44
Idaho§	_	3	12	158	170	_	4	19	237	174	_	0	1	6	6
Montana [§] Nevada [§]	1	2 1	8 8	100 89	96 104	_	1 43	7 87	57 1,781	175 2,528	_	0	1 2	2 9	— 14
New Mexico§		2	5	94	73	_	30	58	1,432	1,576	_	1	4	37	28
Utah Wyoming [§]	13	6 1	32 4	402 35	405 35	19 1	17 1	35 5	715 68	770 115	1	0	3 1	33 5	14 3
Pacific	42	61	558	2,911	2,513	282	691	871	30,987	36,612	1	2	16	104	100
Alaska California	4 27	1 43	5 93	69 1,982	103 2,004	8 247	10 604	27 734	435 27,376	545 30,177	1	0	3 10	13 34	10 29
Hawaii	_	1	4	· —	46	_	10	15	· —	824	_	1	2	_	18
Oregon [§] Washington	11	9 8	17 449	397 463	360	11 16	23 48	63 142	982 2,194	1,279 3,787	_	1 0	6 5	55 2	43
American Samoa	U	0	0	U	U	U	0	2	Ú	U	U	0	0	U	U
C.N.M.I. Guam	U —			U _	U —	U —	_ 1	38	U 97	U 94	U —			U —	U 1
Puerto Rico	_	4	15	165	234	_	5	23	281	275	_	0	1	2	3
U.S. Virgin Islands	U	0	0	U	U	U	1	3	U	U	U	0	0	U	U

Max: Maximum.

C.N.M.I.: Commonwealth of Northern Mariana Islands.
U: Unavailable. —: No reported cases. N: Not notifiable. Cum: Cumulative year-to-date counts. Med: Med: * Incidence data for reporting year 2007 are provisional.
Data for *H. influenzae* (age <5 yrs for serotype b, nonserotype b, and unknown serotype) are available in Table I. Contains data reported through the National Electronic Disease Surveillance System (NEDSS).

TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending November 17, 2007, and November 18, 2006 (46th Week)*

			Hepat A	itis (viral, a	acute), by	type [†]		В				Le	egionellos	sis	
		Previ					Prev						/ious	313	
Reporting area	Current week	52 we	eeks Max	Cum 2007	Cum 2006	Current week	52 w Med	eeks Max	Cum 2007	Cum 2006	Current week	52 w Med	reeks Max	Cum 2007	Cum 2006
United States	15	52	201	2,437	3,114	28	77	405	3,472	3,920	34	43	106	2,069	2,457
New England	1	2	6	109	167	1	1	5	67	108	1	2	13	115	164
Connecticut Maine [§]	_	0 0	3 1	25 3	37 8	_	0	5 2	28 12	46 22	_ 1	0	5 1	36 7	48 9
Massachusetts	_	1	4	49	80	_	0	1	4	19		0	3	21	65
New Hampshire Rhode Island§	_ 1	0 0	3 2	12 12	22 12	_	0	1 3	5 13	9 9	_	0	2 6	8 34	13 21
Vermont [§]	<u>.</u>	0	1	8	8	1	ő	1	5	3	_	ő	2	9	8
Mid. Atlantic	1	8	19	373	355	1	8	21	394	474	12	11	36	646	892
New Jersey New York (Upstate)	_ 1	2 1	6 11	93 67	100 82	_ 1	1 2	8 13	79 82	153 57	<u> </u>	1 4	11 22	76 204	111 304
New York City	_	3	8	137	111	_	2	6	84	109	_	2	10	103	173
Pennsylvania	_	1	5	76	62	_	3	8	149	155	6	4	21	263	304
E.N. Central Illinois	3	6 2	13 5	261 92	324 95	2	9 2	23 6	379 99	446 120	8	8 1	27 12	469 83	551 116
Indiana Mishigan		0	7	29 74	24	_	0 2	21	47	52 128	2	1	7	49 137	46
Michigan Ohio	1	1 1	8 4	74 59	115 49	2	2	8 7	96 117	113	5	3 3	10 17	190	135 210
Wisconsin	_	0	3	7	41	_	0	3	20	33	_	0	2	10	44
W.N. Central lowa	_	2 1	18 4	150 39	122 11	2	2	15 3	118 21	131 19	2	1 0	9 1	89 9	77 10
Kansas	_	0	1	6	26	_	0	2	9	10	_	0	1	3	8
Minnesota Missouri	_	0	17 2	62 25	17 42	_	0 1	13 5	18 55	18 61	2	0 1	6 3	25 37	24 21
Nebraska [§]	_	0	2	12	17	_	0	1	10	18	_	0	2	11	9
North Dakota South Dakota	_	0 0	3 1	<u> </u>	<u> </u>	_	0	1 1	 5	 5	_	0	1 1	4	 5
S. Atlantic	6	10	21	453	503	10	18	56	855	1,087	5	7	25	346	420
Delaware	_	0	1	7	13	_	0	2	15	46	_	0	2	8	12
District of Columbia Florida	3	0 3	5 7	14 140	7 193	4	0 7	2 14	1 306	7 372	_	0 2	2 10	1 137	29 141
Georgia	_	1	4	63	51	2	2	7	109	184	1	0	2	21	32
Maryland [§] North Carolina	_ 1	1 0	5 11	70 57	59 94	2	2	6 16	101 120	137 147	3	1 1	4 4	67 42	97 33
South Carolina§	1	0	4	16	23	_	1	5	53	84	_	0	2	17	6
Virginia [§] West Virginia	1	1 0	5 2	78 8	57 6	2	3 0	8 23	111 39	62 48	1	1 0	4 4	41 12	57 13
E.S. Central	_	2	5	90	115	1	7	14	313	298	1	2	6	86	99
Alabama [§] Kentucky	_	0 0	3 2	16 19	13 31	_	2 1	7 7	109 65	89 67	_	0 1	1 4	9 43	9 43
Mississippi	_	0	4	8	8	_	0	8	25	11	_	Ö	1	_	4
Tennessee§	_	1	5	47	63	1	3	8	114	131	1	1	4	34	43
W.S. Central Arkansas§	_	5 0	43 2	210 10	344 45	6	17 1	169 7	757 59	802 70	2	2	16 3	102 8	60 4
Louisiana	_	1	3	26	29	_	1	4	63	50	_	0	1	3	10
Oklahoma Texas [§]	_	0 3	8 39	11 163	6 264	<u> </u>	1 12	38 135	115 520	69 613		0 2	6 13	5 86	1 45
Mountain	4	5	15	227	250	1	3	7	151	125	3	2	7	104	116
Arizona	2	3	11	162	153	_	1	4	49	U	1	0	5	39	35
Colorado Idaho§		0 0	3 1	21 6	36 9	_	0	3 1	30 12	32 13	1	0 0	2 1	21 6	25 11
Montana [§] Nevada [§]	_	0	2 2	9 9	11 11	_	0 1	3 3	 29	2 34	_	0	1 2	3 7	6 10
New Mexico§	_	0	2	10	14	_	0	2	10	34 22	_	0	2	8	5
Utah Wyoming [§]	_	0	2 1	7 3	14 2	1	0	4 1	19 2	22	1	0	3 1	17 3	24
Pacific		12	92	564	934	4	10	106	438	449		2	11	112	78
Alaska	_	0	1	4	1	_	0	1	7	8	_	0	1	_	1
California Hawaii	_	10 0	40 1	489	884 12	2	7 0	31 1	327	359 7	_	1 0	11 0	84	77
Oregon§	_	1	2	27	37	_	1	4	55	75	_	Ō	1	9	_
Washington	 U	0	52	44	_	2 U	1	74	49	_	_	0	3	19	
American Samoa C.N.M.I.	U	0	0	U U	U U	U	0	0	U U	U U	U U	0	0	U U	U U
Guam Puerto Rico	_	0 1	0 10	— 45	— 61	_	0 1	0 9	— 44	<u> </u>	_	0	0 2	_ 3	_ 1
U.S. Virgin Islands	U	0	0	45 U	U	U	0	0	44 U	U	U	0	0	U	ΰ

C.N.M.I.: Commonwealth of Northern Mariana Islands.
U: Unavailable. —: No reported cases. N: Not notifiable. Cum: Cumulative year-to-date c * Incidence data for reporting year 2007 are provisional.
Data for acute hepatitis C, viral are available in Table I.
Contains data reported through the National Electronic Disease Surveillance System (NEDSS). Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum.

TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending November 17, 2007, and November 18, 2006 (46th Week)*

			.yme disea	ase				lalaria			Mer		ccal disea I serogrou	se, invasiv ıps	∕e [†]
	_		vious	_				ious		_			vious		_
Reporting area	Current week	Med Med	eeks Max	Cum 2007	Cum 2006	Current week	Med Med	eeks Max	Cum 2007	Cum 2006	Current week	Med V	veeks Max	Cum 2007	Cum 2006
United States	211	262	1,228	18,290	17,792	7	20	105	959	1,272	7	21	87	897	986
New England Connecticut Maine [§] Massachusetts New Hampshire Rhode Island [§]	41 28 11 —	40 11 4 2 7 0	300 214 61 27 86 93	3,324 1,601 447 211 785 151	4,196 1,635 259 1,421 598 186	_ _ _ _	1 0 0 0 0	5 3 2 3 4 1	49 1 7 29 8	49 10 4 24 9	_ _ _ _	1 0 0 0 0	3 1 1 2 1	38 6 7 19 1 2	47 10 7 22 4 2
Vermont§	2	2	13	129	97	_	0	2	4	i	=	0	i	3	2
Mid. Atlantic New Jersey New York (Upstate) New York City Pennsylvania	81 — 66 — 15	110 26 52 1 40	624 146 426 22 306	9,135 1,942 3,035 169 3,989	9,092 2,334 3,385 291 3,082	2 - 2 - -	5 0 1 3 1	14 2 5 7 4	234 — 59 139 36	334 85 41 163 45	1 1 —	3 0 1 0	8 2 3 4 5	122 13 35 26 48	149 18 32 57 42
E.N. Central Illinois Indiana Michigan Ohio Wisconsin	_ _ _ _ _	8 0 0 0 0	151 12 7 5 3 138	1,278 112 41 53 19 1,053	1,667 109 21 53 42 1,442	_ _ _ _	2 1 0 0 0	6 6 2 2 2 2	97 41 9 16 22 9	152 79 11 18 27 17	3 1 1 1	3 1 0 0 1 0	9 3 4 3 2 3	133 42 25 25 32 9	151 39 22 26 44 20
W.N. Central lowa Kansas Minnesota Missouri Nebraska [§] North Dakota South Dakota	53 — 50 2 1 —	5 1 0 1 0 0 0	195 11 2 188 6 1 7	582 109 9 423 31 7 3	717 95 4 601 5 11 —	2 1 1	0 0 0 0 0 0 0	12 1 1 11 1 1 1	37 3 16 6 2 1	57 2 7 37 6 3 1	=	1 0 0 0 0 0 0	5 3 1 3 2 3 1	59 14 2 18 15 5 2	58 17 4 13 14 6 1
S. Atlantic Delaware District of Columbia Florida Georgia Maryland [§] North Carolina South Carolina [§] Virginia [§] West Virginia	29 4 — — 13 1 — —	66 12 0 1 0 30 0 0 13	176 34 7 11 1 112 8 2 61	3,683 648 13 77 3 2,040 43 23 769 67	1,953 451 56 25 8 1,096 29 18 257 13	3 1 2	4 0 0 1 0 1 0 0 1	13 1 2 7 5 5 4 1 5	224 4 3 53 31 54 20 6 51	309 5 5 53 82 73 28 9 52 2	1 1 	3 0 0 1 0 0 0 0	11 1 7 5 2 6 2 2 2	150 1 58 24 20 18 14 13 2	176 4 1 66 15 14 30 20 18
E.S. Central Alabama [§] Kentucky Mississippi Tennessee [§]	_ _ _ _	1 0 0 0	5 3 2 1 4	50 12 5 1 32	34 10 7 3 14	_ _ _ _	0 0 0 0	3 1 1 1 2	31 5 8 2 16	23 9 3 6 5	1 - 1 -	1 0 0 0	4 2 2 4 2	44 8 10 10 16	40 5 11 5 19
W.S. Central Arkansas [§] Louisiana Oklahoma Texas [§]	2 — — — 2	1 0 0 0 1	6 1 1 0 6	64 1 2 — 61	23 — 1 — 22	_ _ _ _	1 0 0 0 1	29 1 2 3 25	76 2 14 5 55	93 4 8 7 74	_ _ _ _	2 0 0 0 1	15 2 4 4 11	89 9 25 16 39	87 10 34 11 32
Mountain Arizona Colorado Idaho§ Montana§ Nevada§ New Mexico§ Utah Wyoming§	_ _ _ _ _ _	1 0 0 0 0 0 0 0	4 1 2 2 2 1 2 1	38 2 2 8 4 8 4 7 3	28 10 — 6 — 3 3 5	_ _ _ _ _ _	1 0 0 0 0 0 0	6 3 2 2 1 1 1 3 0	58 12 23 3 3 2 4 11	71 23 19 1 2 4 5	_ _ _ _ _ _	1 0 0 0 0 0 0	4 2 2 1 1 1 1 2	57 12 21 3 2 4 2 11	65 15 20 3 5 6 6 6
Pacific Alaska California Hawaii Oregon [§] Washington	5 1 4 N —	2 0 2 0 0	16 1 9 0 1 8	136 8 122 N 3 3	82 3 73 N 6	_ _ _ _ _	3 0 2 0 0	45 1 7 0 3 43	153 2 112 — 14 25	184 23 142 8 11	1 1 - -	4 0 3 0 0	48 1 10 1 3 43	205 1 153 — 30 21	213 3 164 9 37
American Samoa C.N.M.I. Guam Puerto Rico U.S. Virgin Islands	U N 	0 0 0 0	0 0 0 0	U N U	U U N U	U - -	0 0 0 0	0 0 1 0	U - 3 U	U U - 2 U	U U — U	0 0 0 0	0 0 1 0	 6 	

C.N.M.I.: Commonwealth of Northern Mariana Islands.
U: Unavailable. —: No reported cases. N: Not notifiable. Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum.

* Incidence data for reporting year 2007 are provisional.

* Data for meningococcal disease, invasive caused by serogroups A, C, Y, & W-135; serogroup B; other serogroup; and unknown serogroup are available in Table I.

* Contains data reported through the National Electronic Disease Surveillance System (NEDSS).

TABLE II. (*Continued*) Provisional cases of selected notifiable diseases, United States, weeks ending November 17, 2007, and November 18, 2006 (46th Week)*

(46th Week)*			Pertussis	s			Rab	ies, anim	al		R	ocky Mo	untain sp	otted feve	r
	Current		rious	C	C	C		/ious	C	C	C		vious	C	
Reporting area	week	Med	eeks Max	Cum 2007	Cum 2006	Current week	Med	reeks Max	Cum 2007	Cum 2006	Current week	Med	veeks Max	Cum 2007	Cum 2006
United States	66	172	1,479	7,643	12,596	37	101	177	4,894	5,079	21	32	211	1,818	1,962
New England	1	27	77 5	1,182	1,621	9	11	22 10	530 208	444 192	_	0	10 0	5	11
Connecticut Maine†	_	1 1	13	59 73	110 132	3 1	4 2	5	208 79	113	_	0	1	1	N
Massachusetts New Hampshire	_	22 1	39 6	928 52	1,027 202		0 1	0 4	— 51	N 45	_	0	1 0	4	10 1
Rhode Island† Vermont†	1	0	31 9	23 47	49 101	- 3	0 3	4 13	37 155	30 64	_	0	9	_	
Mid. Atlantic	10	23	155	1,017	1,667	8	22	56	1,217	491	_	1	6	60	84
New Jersey	7	3	11	139	273	N	0	0	N	N	_	0	2	9	38
New York (Upstate) New York City	_	11 2	146 6	506 105	757 93	<u>8</u>	11 1	20 5	482 42	N 34	_	0 0	1 3	3 26	23
Pennsylvania	3	6	15	267	544	_	13	44	693	457	_	0	3	22	23
E.N. Central Illinois	5 —	28 3	79 23	1,229 130	2,011 505	2 1	4 1	48 15	380 113	157 46	_	1 0	4 3	42 24	63 26
Indiana Michigan	_	0 7	45 18	52 254	204 559	_ 1	0 1	1 27	12 179	11 46	_	0	2 1	4 4	6 4
Ohio	5	13	54	594	541	_	1	11	76	54	_	0	2	10	26
Wisconsin W.N. Central	 5	3 13	24 151	199 594	202 1,142	N _	0 5	0 13	N 244	N 290	_	0 5	0 32	374	1 192
Iowa	_	2	16	122	284	_	0	3	30	57	_	0	4	14	5
Kansas Minnesota	_	3 0	12 119	122 157	277 161	_	2 0	5	101 32	71 38	_	0 0	1 1	1 1	1 3
Missouri Nebraska [†]	2	1 1	9 12	72 59	285 90	_	0	3 0	39	63	_	4 0	26 2	340 14	158 25
North Dakota South Dakota	_	0	18 7	8 54	25 20	_	0	6 2	21 21	24 37	_	0	0 1	4	
S. Atlantic	13	16	163	836	1,005	— 15	40	76	1,897	2,110	20	12	112	882	1,094
Delaware		0	2	11	3	_	0	0			_	0	2	14	21
District of Columbia Florida	4	0 4	1 18	2 198	6 192	_	0	29	110	176	_	0	1 4	1 21	1 14
Georgia Maryland [†]		0 2	4 8	27 107	92 133	12	3 7	34 18	246 327	244 385	1 1	0 1	5 7	35 60	51 77
North Carolina South Carolina [†]	6	3 2	112 9	288 66	177 172	3	9	19 11	447 46	479 160	18	4 1	96 7	563 60	794 38
Virginia [†]	1	2	11	108	187	_	13	31	646	568	_	2	11	123	95
West Virginia E.S. Central	1	0 6	19 32	29 369	43 323	_	0 3	11 9	75 140	98 231	_	0 4	3 16	5 241	3 356
Alabama†		2	18	79	81	_	0	2	_	78	_	1	9	82	84
Kentucky Mississippi	_	0 1	4 29	22 194	56 34	_	0	3 1	18 1	27 4	_	0	2	5 14	3 8
Tennessee [†]	1	1	7	74	152	_	3	7	121	122	_	2	10	140	261
W.S. Central Arkansas†	1 1	19 1	226 17	833 133	785 86	1 1	1 0	27 5	74 29	917 31	1 1	1 0	168 53	173 91	114 51
Louisiana Oklahoma	_	0	1 36	14 6	24 19	_	0	1 22	— 45	6 60	_	0	1 108	2 47	5 29
Texas [†]	_	16	174	680	656	_	0	20	45	820	_	0	7	33	29
Mountain Arizona	10	22 4	61 13	1,004 182	2,317 478	_	3 2	14 12	208 144	207 134	_	0	4 1	33 7	46 11
Colorado	5	6	14	271	680	_	0	0	_	_	_	0	2	4	4
Idaho [†] Montana [†]	_	0	5 7	34 38	83 113	_	0	0 3	 18	24 15	_	0 0	1 1	4 1	14 2
Nevada [†] New Mexico [†]	_	0	5 7	12 65	66 127	_	0	1 2	2 10	5 10	_	0	0	_ 4	_ 8
Utah	5	8	47	380	695	_	0	2	16	11	_	0	1	1	_
Wyoming [†] Pacific	20	0 11	4 547	22 579	75 1,725	_ 2	0 4	4 10	18 204	8 232	_	0	2	12 8	7 2
Alaska	_	0	8	50	89	_	0	6	39	16	N	0	0	N	N
California Hawaii	_	3 0	167 1	157 —	1,453 85	2 N	3 0	8 0	154 N	191 N	N	0 0	3 0	6 N	N
Oregon [†] Washington	 20	2 2	14 377	112 260	98	_	0	3 0	11	25	N	0	1 0	2 N	2 N
American Samoa	U	0	0	200 U	U	U	0	0	U	U	U	0	0	U	U
C.N.M.I. Guam	Ü	_ 0	_ 1	Ŭ —	U 63	Ü	_ 0		Ü	Ü	Ü	_ 0	<u>_</u>	Ü	U N
Puerto Rico	_	0	0	_	3		0	5	37	75	N	0	0	N	N
U.S. Virgin Islands	U	0	0	U	U	U	0	0	U	U	U	0	0	U	U

C.N.M.I.: Commonwealth of Northern Mariana Islands.
U: Unavailable. —: No reported cases. N: Not notifiable. Cum: Cumulative year-to-date c

* Incidence data for reporting year 2007 are provisional.

Contains data reported through the National Electronic Disease Surveillance System (NEDSS). Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum.

TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending November 17, 2007, and November 18, 2006 (46th Week)*

(40tii Week)		s	almonello	sis		Shigat	oxin-pro	ducing E	. coli (STE	EC)†		,	Shigellos	is	
	Current		rious eeks	Cum	Cum	Current		/ious reeks	Cum	Cum	Current		vious veeks	Cum	Cum
Reporting area	week	Med	Max	2007	2006	week	Med	Max	2007	2006	week	Med	Max	2007	2006
United States	463	865	2,338	38,905	39,276	38	80	336	4,027	3,608	297	348	1,287	14,925	12,609
New England Connecticut Maine [§] Massachusetts New Hampshire Rhode Island [§] Vermont [§]	4 -2 -1 -1	37 0 3 24 3 2	406 391 14 57 10 20 5	2,035 391 129 1,198 148 94 75	2,091 503 122 1,115 200 83 68		4 0 1 2 0 0	67 61 4 10 4 2	269 61 38 130 21 6 13	264 75 42 95 25 8	_ _ _ _ _	4 0 0 3 0 0	43 40 5 8 2 9	224 40 14 144 5 18	259 67 4 161 8 13 6
Mid. Atlantic New Jersey New York (Upstate) New York City Pennsylvania	26 — 19 — 7	100 16 27 24 33	184 36 112 51 69	4,953 723 1,310 1,235 1,685	4,893 1,013 1,181 1,151 1,548	5 -3 - 2	8 1 3 0 3	63 20 15 5 47	412 48 189 43 132	434 113 153 42 126	10 7 2 1	12 2 3 5 2	47 10 42 11 21	651 114 147 239 151	818 280 204 250 84
E.N. Central Illinois Indiana Michigan Ohio Wisconsin	28 	101 31 15 18 27 16	252 186 54 41 65 50	5,058 1,589 656 823 1,216 774	5,077 1,437 789 907 1,120 824	7 	10 1 1 1 3 3	34 10 13 8 11 10	581 85 95 88 151 162	626 101 80 86 171 188	22 5 17 	33 11 2 1 15 3	131 32 13 7 104 13	1,974 467 129 66 1,106 206	1,282 581 153 145 172 231
W.N. Central lowa Kansas Minnesota Missouri Nebraska [§] North Dakota South Dakota	19 2 — 10 3 3 1	50 9 7 13 15 5 0 3	102 19 20 44 31 12 23 11	2,541 425 368 631 692 235 43 147	2,407 421 334 626 690 176 29 131	11 — 9 1 1	13 3 1 4 2 1 0	45 38 4 17 12 6 12 5	726 170 53 239 135 80 4 45	600 116 23 183 151 72 6 49	25 — 2 21 2 —	34 2 0 5 22 0 0	156 14 3 24 72 7 127 30	1,663 80 25 222 1,193 24 7 112	1,590 105 131 201 613 118 94 328
S. Atlantic Delaware District of Columbia Florida Georgia Maryland [§] North Carolina South Carolina [§] Virginia [§] West Virginia	226 — 122 31 18 20 18 17 —	222 2 0 85 34 15 28 18 20 3	429 8 4 181 88 43 110 51 38 31	10,590 129 16 4,298 1,900 804 1,388 956 924 175	10,351 142 57 4,264 1,658 705 1,508 973 920 124	7 — 5 — 2 —	15 0 0 3 2 2 1 0 3 0	37 3 1 13 9 6 24 3 9 5	643 14 1 144 97 86 124 18 141	563 10 2 78 79 113 104 13 152	54 — 13 21 2 10 3 5	88 0 0 42 30 2 0 2 3	177 2 5 75 95 7 14 20 11 36	4,105 10 4 2,032 1,502 98 94 155 150 60	3,050 10 15 1,398 1,179 123 143 77 101 4
E.S. Central Alabama [§] Kentucky Mississippi Tennessee [§]	34 9 2 3 20	57 16 10 13 17	141 78 22 101 34	2,904 840 512 802 750	2,558 699 414 741 704	_ _ _ _	4 1 2 0 2	26 19 12 1	292 62 111 5 114	282 29 93 10 150	39 7 8 12 12	30 13 4 10 4	172 34 35 108 27	2,410 625 445 1,082 258	749 279 229 95 146
W.S. Central Arkansas [§] Louisiana Oklahoma Texas [§]	26 11 — 15 —	82 13 14 9 41	595 51 35 103 470	3,787 768 658 589 1,772	4,710 843 1,025 454 2,388	_ _ _ _	3 1 0 0 2	73 3 2 8 68	152 34 3 17 98	215 46 17 35 117	119 3 — — 116	40 2 8 3 24	655 10 22 63 580	1,772 84 379 119 1,190	1,763 109 235 121 1,298
Mountain Arizona Colorado Idaho ^{\$} Montana ^{\$} Nevada ^{\$} New Mexico ^{\$} Utah Wyoming ^{\$}	42 27 7 3 — — — 1 4	50 17 11 3 2 3 5 5	90 44 24 9 6 10 13 18 4	2,357 899 519 127 92 148 234 272 66	2,357 792 556 160 120 205 238 243 43	1 - - - - - 1	9 2 1 2 0 0 0 1	42 8 17 16 0 3 3 9	510 101 144 122 — 18 34 91	505 100 104 94 — 30 46 112 19	10 6 4 — — — —	18 9 2 0 0 0 2 1	57 33 6 2 13 9 4 5	851 505 111 11 22 47 89 34 32	1,335 657 218 14 52 127 170 65 32
Pacific Alaska California Hawaii Oregon§ Washington	58 41 17	107 1 87 4 7 11	890 5 260 16 15 625	4,680 72 3,739 — 276 593	4,832 69 4,144 236 381 2	7 N 5 —	7 0 4 0 1	164 0 33 1 11 162	442 N 235 — 79 128	119 N N 17 102	18 — 13 — — 5	28 0 24 0 1 2	256 2 84 0 6 170	1,275 7 1,062 — 72 134	1,763 7 1,597 45 114
American Samoa C.N.M.I. Guam Puerto Rico U.S. Virgin Islands	U U — U	0 0 11 0	0 0 66 0	U U - 446 U	U U 613 U	U N — U	0 0 0 0	0 0 0 0	U U N U	U N — U	U - -	0 0 0 0	0 0 4 0	U U 18 U	U U - 38 U

C.N.M.I.: Commonwealth of Northern Mariana Islands.
U: Unavailable. —: No reported cases. N: Not notifiable. Cum: Cumulative year-to-date counts. Med: Me

* Incidence data for reporting year 2007 are provisional.
Includes E. coli O157:H7; Shiga toxin-positive, serogroup non-O157; and Shiga toxin-positive, not serogrouped.

Scontains data reported through the National Electronic Disease Surveillance System (NEDSS). Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum.

TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending November 17, 2007, and November 18, 2006 (46th Week)*

(46th Week)*	Stre	eptococca	l disease,	invasive, gr	oup A	Streptococc	us pneumon	iae, invasiv Age <5 ye		nondrug resistant†
Penorting area	Current	Prev 52 w	ious	Cum 2007	Cum 2006	Current week		vious veeks Max	Cum 2007	Cum 2006
Reporting area United States	53	97	261	4,238	4,685	16	29	108	1,355	1,182
New England	3	5	28	349	316	—	29	11	1,333	109
Connecticut	2	0	23	114	83	_	0	6	15	31
Maine§	1	0	3	25	17	_	0	1	2	_
Massachusetts New Hampshire	_	3 0	12 4	155 33	160 35	_	2 0	6 2	72 10	64 9
Rhode Island [§]	_	0	12	6	7	_	0	2	8	5
/ermont [§]	_	0	2	16	14	_	0	1	2	_
/lid. Atlantic	4	17	41	787	847	1	4	37	228	169
lew Jersey lew York (Upstate)	_	2 5	10 27	113 258	137 270		1 2	4 15	31 92	56 85
lew York City	_	4	13	182	151	_	1	35	105	28
ennsylvania	4	5	11	234	289	N	0	0	N	N
.N. Central	9	16	34	720	886	3	4	14	189	312
linois ndiana		4 2	13 12	199 108	268 106	_	1 0	6 10	39 18	87 47
lichigan	3	4	10	178	187	3	1	4	65	70
)hio T	4	4	14	204	215	_	1	7	55	65
Visconsin	_	0	6	31	110	_	0	2	12	43
V.N. Central owa	11 —	5 0	32 0	302	315	2	2 0	8 0	108	102
ansas	_	0	3	30	<u> </u>	_	0	1	3	11
Minnesota	5	0	29	149	143	_	1	6	70	64
∕lissouri Iebraska§	3	2 0	6 3	72 23	71 29		0	2 1	20 14	14 10
lorth Dakota	3	0	2	18	12	_	0	2	14	3
South Dakota	_	0	2	10	10	_	0	0	_	_
S. Atlantic	20	22	52	1,119	1,067	4	4	14	242	76
Delaware District of Columbia	_	0 0	1 3	10 8	10 15	_	0 0	0 1	_	
Florida	11	6	16	287	271		1	5	61	
Georgia	4	5	13	226	230	_	0	5	44	-
∕laryland [§] Iorth Carolina	3	4 1	10 22	192 150	195 148	2	1 0	5 0	57 —	63 —
South Carolina§		i	7	85	57	_	1	4	42	_
/irginia [§]	2	2	11	136	116	_	0	4	31	
Vest Virginia	_	0	3	25	25	_	0	4	7	12
E.S. Central		4	13	189	187	1	2	6	82	17 N
Alabama§ Kentucky	N —	0 1	0 3	N 35	N 41	N N	0	0 0	N N	N N
/lississippi	N	0	0	N	N	_	0	2	3	17
ennessee§	_	3	13	154	146	1	1	6	79	_
V.S. Central	2	6	90	271	351	1	4	43	197	193
Arkansas§ ₋ouisiana	_	0 0	2 4	17 16	24 16	_	0 0	2 4	10 27	20 22
Oklahoma	_	1	23	64	94	_	1	13	48	51
exas [§]	2	3	64	174	217	1	2	27	112	100
Mountain	4	10	22	472	598	4	4	12	174	180
Arizona Colorado	1 2	4 3	11 8	184 132	309 109	2 2	2 1	7 4	100 43	97 51
daho§	_	0	2	16	8	_	0	1	2	3
Montana§	N	0	0	N	N	N	0	0	N	N
levada§ lew Mexico§	_	0 1	1 4	2 51	112	_	0 0	1 4	1 21	2 27
Jtah	1	2	7	82	56	_	0	2	7	_
Vyoming§	_	0	1	5	4	_	0	0	_	_
acific	_	1	9	29	118	_	0	2	26	24
llaska California	 N	0 0	3 0	29 N	N N	N	0	2 0	26 N	N N
ławaii	_	3	9	_	118	_	1	2	_	24
Oregon§	N	0	0	N	N	N	0	0	N	N
Vashington	N	0	0	N	N	N	0	0	N 	N
American Samoa C.N.M.I.	U U	0	0	U U	U U	U U	0	0	U U	U U
iuam	_	0	0	_	_	N N	0	0	N	N
Puerto Rico		0	0			N	0	0	N	N
.S. Virgin Islands	U	0	0	U	U	U	0	0	U	U

C.N.M.I.: Commonwealth of Northern Mariana Islands.
U: Unavailable. —: No reported cases. N: Not notifiable. Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum.

* Incidence data for reporting year 2007 are provisional.
Includes cases of invasive pneumococcal disease, in children aged <5 years, caused by *S. pneumoniae*, which is susceptible or for which susceptibility testing is not available (NNDSS event code 11717).

Contains data reported through the National Electronic Disease Surveillance System (NEDSS).

TABLE II. (*Continued*) Provisional cases of selected notifiable diseases, United States, weeks ending November 17, 2007, and November 18, 2006 (46th Week)*

		St			oniae, inva	sive disease									
			All ages					e <5 years	S		Sy			d seconda	ary
	Cumant	Previ		C	C	Cumant		vious	C:	C	Commont		vious	C	C
Reporting area	Current week	Med 52 we	Max	Cum 2007	Cum 2006	Current week	Med	veeks Max	Cum 2007	Cum 2006	Current week	Med	veeks Max	Cum 2007	Cum 2006
United States	19	46	256	2,019	2,100	3	8	35	396	358	67	201	310	9,198	8,475
New England	_	2	12	89	114	_	0	3	11	4	5	5	14	234	174
Connecticut	_	1	5	50	87	_	0	2	4	_	2	0	10	30	38
Maine§ Massachusetts	_	0 0	2	9	7	_	0	2	2	1	3	0 3	2 8	9 141	8 106
New Hampshire	_	0	0	_	_	_	0	0	_	_	_	0	3	26	11
Rhode Island [§] Vermont [§]	_	0 0	4 2	15 15	9 11	_	0	1 1	3 2	3	_	0	5 1	26 2	9 2
Mid. Atlantic	2	2	9	110	136	_	0	5	23	21	9	27	45	1,326	1,016
New Jersey	_	0	0	_	_	_	0	0	_	_	_	4	8	180	153
New York (Upstate) New York City	1	1 0	5 0	36 —	44	_	0	4 0	7	9	4	3 17	14 35	123 808	133 491
Pennsylvania	1	1	6	74	92	_	0	2	16	12	5	4	10	215	239
E.N. Central	6	10	40	492	445	1	2	8	95	75	13	15	27	699	790
Illinois Indiana	_	0 3	8 31	54 124	22 125	_	0	5 5	30 23	6 21	9	7 1	14 6	324 50	381 82
Michigan	_	0	1	2	16	_	0	1	1	2	2	2	9	103	104
Ohio Wisconsin	6 N	5 0	38 0	312 N	282 N	1	1 0	5 0	41	46	2	4 1	9 4	172 50	161 62
W.N. Central	_	2	124	120	89	_	0	15	10	13	3	7	14	309	257
Iowa	_	0	0	_	_	_	0	0	_	_	_	0	2	15	18
Kansas Minnesota	_	0 0	11 123	64	— 51	_	0	2 15	6	10	_	0 1	2 4	20 62	24 44
Missouri	_	1	5	47	36	_	0	0	_	3	3	4	11	203	151
Nebraska [§] North Dakota	_	0 0	1 0	2	1	_	0	0 0	_	_	_	0	1 0	_	7 1
South Dakota	_	Ő	3	7	1	_	0	1	4	_	_	Ö	3	7	12
S. Atlantic	11	20	59	885	998	1	4	15	189	173	10	50	180	2,183	1,917
Delaware District of Columbia	_	0	1	8 5	 24	_	0	1 0	2		_	0 3	3 12	15 157	17 105
Florida	9	11	29	510	528	1	2	8	108	110	_	17	44	823	656
Georgia Maryland [§]	2	7 0	17 1	306 1	345	_	1 0	10 0	71 —	61 —	_	7 6	153 15	337 269	360 271
North Carolina	_	0	Ö		_	_	0	0	_	_	5	5	23	291	270
South Carolina§ Virginia§	N	0	0	N	 N	_	0	0	_	_	 5	2 4	11 16	86 200	60 169
West Virginia	_	1	17	55	101	_	0	1	8	_	_	0	1	5	9
E.S. Central	_	3	9	143	163	1	0	3	33	29	8	18	30	785	642
Alabama [§] Kentucky	_N	0 0	0 2	N 21	N 32	_	0	0 1	_ 3	 6	_ 1	7 1	16 7	304 54	283 63
Mississippi	_	0	2	_	22	_	0	Ó	_	_	_	2	9	96	68
Tennessee§	_	2	8	122	109	1	0	3	30	23	7	7	15	331	228
W.S. Central	_	2	12	124	72	_	0	3	17	8	7	35	55	1,620	1,403
Arkansas§ Louisiana	_	0 1	1 4	3 53	10 62	_	0	0 2	7	2 6	6 1	2 9	10 23	114 417	74 287
Oklahoma	_	0	10	68	_	_	0	2	10	_	_	1 21	4	53	63
Texas [§]		0 1	0 6	— 56	— 83	_	0	0 3		35	1	ے 8	39 24	1,036 332	979
Mountain Arizona	_	0	0	56	83	_	0	0	18	35		3	22	332 149	441 171
Colorado		0	0	_	_	_	0	0	_	_	_	1	5	35	61
Idaho§ Montana§	N —	0	0	N —	N —	_	0	0	_	_	_	0	1 2	1 3	3 1
Nevada§	_	0	3	18	16	_	0	2	5	2	_	2	6	87	121
New Mexico [§] Utah	_	0 0	0 6	24	— 35	_	0	0 3	11	23	_ 1	1 0	7 2	38 16	67 17
Wyoming [§]	_	Ö	2	14	32	_	Ö	1	2	10		Ö	1	3	
Pacific	_	0	0	_	_	_	0	0	_	_	11	39	59	1,710	1,835
Alaska California	N	0	0	N	N N	_	0	0	_	_	3	0 36	1 56	7 1,565	11 1,631
Hawaii	_	0	0	_	_	_	0	0	_	_	_	0	1	· —	17
Oregon [§] Washington	N N	0	0	N N	N N	_	0	0 0	_	_	 8	0 2	6 12	15 123	18 158
American Samoa	U	0	0	U	U	U	0	1	U	U	U	0	0	U	U
C.N.M.I.	Ü	_	_	Ü	Ü	Ü	_	_	ŭ	ŭ	Ü	_	_	U	Ü
Guam Puerto Rico	N N	0	0	N N	N N	_	0	0	_	_	8	0 3	1 10	3 145	132
U.S. Virgin Islands	U	0	0	U	U	U	0	0	U	U	Ů	0	0	145 U	132 U

C.N.M.I.: Commonwealth of Northern Mariana Islands.
U: Unavailable. —: No reported cases. N: Not no —: No reported cases. N: Not notifiable. Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum.

^{*} Incidence data for reporting year 2007 are provisional.

† Incidence data for reporting year 2007 are provisional.

† Includes cases of invasive pneumococcal disease caused by drug-resistant *S. pneumoniae* (DRSP) (NNDSS event code 11720).

§ Contains data reported through the National Electronic Disease Surveillance System (NEDSS).

TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending November 17, 2007, and November 18, 2006 (46th Week)*

		7 41 10	ella (chick	IPUA/											
		Prev	ious	· /				roinvasiv rious					neuroinva /ious	191AC,	
	Current		eeks	Cum	Cum	Current		eeks	Cum	Cum	Current		reeks	Cum	Cum
Reporting area	week	Med	Max	2007	2006	week	Med	Max	2007	2006	week	Med	Max	2007	2006
United States	505	776	2,813	30,084	39,809	_	1	134	1,102	1,490	1	2	291	2,234	2,767
New England	15	15	124	629	3,768	_	0	2	7	9	_	0	2	5	3
Connecticut Maine ¹	_	0 0	76 7	2	1,441 214	_	0	2	4	7	_	0	1 0	1	2
Massachusetts	_	0	1	-	1,141	_	0	2	3	2	_	0	2	3	1
New Hampshire Rhode Island ¹	8	7 0	14 0	299	362	_	0	0	_	_	_	0	0 1	1	_
Vermont [¶]	7	5	66	328	610	_	Ö	0	_	_	_	Ö	Ö		_
Mid. Atlantic	2	91	195	3,349	4,476	_	0	3	18	26	_	0	1	6	12
New Jersey New York (Upstate)	N N	0	0	N N	N	_	0	1 0	1	2 8	_	0	0	_	3
New York (Opsiale)		0	0		N —	_	0	3	12	8	_	0	1		4
Pennsylvania	2	91	195	3,349	4,476	_	0	1	5	8	_	0	1	4	1
E.N. Central	121	209	568	8,476	12,973	_	0	18	104	244	_	0	11	59	174
Illinois Indiana	N	3 0	11 0	147 N	128 N	_	0	13 4	60 13	127 27	_	0	8 2	36 10	88 53
Michigan	44	84	258	3,473	4,230	_	Ö	5	13	43	_	Ö	0	_	12
Ohio Wisconsin	77	83 17	449 80	4,018 838	7,698 917	_	0	4 2	13 5	36 11	_	0	3 1	8 5	11 10
						_					_				
W.N. Central lowa	21 N	31 0	136 0	1,440 N	1,613 N	_	0	40 4	240 11	224 22	_	0	116 3	708 15	484 15
Kansas	_	8	52	491	296	_	0	3	13	17	_	0	7	26	13
Minnesota Missouri	 21	0 14	0 78	801	1,186	_	0	9 9	45 56	31 51	_	0	12 2	54 12	34 11
Nebraska ¹	N	0	0	N	N	_	0	5	18	45	_	0	15	126	219
North Dakota South Dakota	_	0 1	60 15	84 64	45 86	_	0	11 9	49 48	20 38	_	0	48 32	316 159	117 75
						_					_				
S. Atlantic Delaware	40	97 1	239 4	4,333 38	4,022 63	_	0	12 1	40 1	18	_	0	6 0	34	14
District of Columbia	_	0	8	14	45	_	0	0	_	_	_	0	0	_	2
Florida Georgia	26 N	23 0	76 0	1,125 N	N N	_	0	1 8	3 23	3 2	_	0	0 4	 25	_ 6
Maryland ¹	N	0	0	N	N	_	0	2	6	10	_	0	2	4	1
North Carolina South Carolina ¹	4	0 22	0 72	949	1,044	_	0	1 2	3 2	1 1	_	0	1	2 2	_
Virginia [¶]	_	20	190	1,200	1,511	_	0	1	2	_	_	0	1	1	5
West Virginia	10	22	50	1,007	1,359	_	0	0	_	1	_	0	0	_	_
E.S. Central Alabama ¹	27 27	9 9	571 571	527 524	28 26	_	0	11 2	66 16	118 8	_	0	14 1	92 6	99
Kentucky	N	0	0	N	N	_	0	1	4	5	_	0	Ö	_	1
Mississippi		0	2	3	2	_	0	7	42	89	_	0	12	83	92
Tennessee ¹	N	0	0	N	N	_	0	1	4	16	_	0	1	3	6
W.S. Central Arkansas ¹	194 8	156 11	1,640 105	8,914 605	10,393 867	_	0	28 5	207 13	371 24	_	0	13 2	90 7	234 5
Louisiana	_	1	11	99	194	_	0	5	25	90	_	0	3	11	87
Oklahoma Texas ¹	186	0 149	0 1,534	8,210	N 9,332	_	0	11 16	52 117	27 230	_	0	7 5	42 30	21 121
Mountain	85	53	131	2,381	2,536		0	36	261	392		1	139	998	1,485
Arizona	_	0	0	2,301	2,550	_	0	7	39	67	_	Ó	12	46	80
Colorado	41	21	62	971	1,341	_	0	17	96	66	_	0	65	459	279
Idaho ¹ Montana ¹	N 13	0 6	0 40	N 366	N N	_	0	2 10	8 37	139 12	_	0	19 30	101 162	857 22
Nevada ¹	_	0	1	1	10	_	0	1	1	34	_	0	3	10	90
New Mexico ¹ Utah	4 27	5 12	37 73	325 684	349 775	_	0	8 8	38 27	3 56	_	0	6 7	22 33	5 102
Wyoming [¶]	_	0	9	34	61	_	Ö	4	15	15	_	Ö	33	165	50
Pacific	_	0	9	35	_	_	0	18	159	88	1	0	23	242	262
Alaska California	_	0	9	35	N N	_	0	0 17	 152	— 81	_ 1	0	0 21	 223	— 197
Hawaii	N	0	0	N	N	_	0	0	_	_		0	0	223 —	_
Oregon [¶]	N	0	0	N	N	_	0	3	7	7	_	0	4	19	62
Washington	N	0	0	N	N	_	0	0	_	_	_	0	0	_	3
American Samoa C.N.M.I.	U	0	0	U U	U	U	0	0	U U	U U	U U	0	0	U	U
Guam	_	4	30	168	243	_	0	0	_	_	_	0	0	_	_
Puerto Rico	_	10	30	467	541	_	0	0	_	_	_	0	0	_	_

C.N.M.I.: Commonwealth of Northern Mariana Islands.
U: Unavailable. —: No reported cases. N: Not notifiable. Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum.

† Incidence data for reporting year 2007 are provisional.
Updated weekly from reports to the Division of Vector-Borne Infectious Diseases, National Center for Zoonotic, Vector-Borne, and Enteric Diseases (ArboNET Surveillance). Data for California serogroup, eastern equine, Powassan, St. Louis, and western equine diseases are available in Table I.

Not notifiable in all states. Data from states where the condition is not notifiable are excluded from this table, except in 2007 for the domestic arboviral diseases and influenzanassociated pediatric mortality, and in 2003 for SARS-CoV. Reporting exceptions are available at http://www.cdc.gov/epo/dphsi/phs/infdis.htm.

Contains data reported through the National Electronic Disease Surveillance System (NEDSS).

TABLE III. Deaths in 122 U.S. cities,* week ending November 17, 2007 (46th Week) All causes, by age (years) All causes, by age (years)												are)			
	All P&I								All causes, by age (years)					P&I [†]	
Reporting Area	Ages	≥65	45-64	25-44	1-24	<1	Total	Reporting Area	Ages	≥65	45-64	25-44	1-24	<1	Total
New England Boston, MA	485 115	343 74	96 32	27 5	3 2	16 2	32 6	S. Atlantic Atlanta, GA	1,115 89	687 56	275 24	80 7	37 1	36 1	56 1
Bridgeport, CT	34	26	5	1	_	2	2	Baltimore, MD	128	80	29	9	8	2	9
Cambridge, MA	14	11	3	_	_	_	1	Charlotte, NC	116	70	27	11	5	3	9
Fall River, MA Hartford, CT	24 50	22 31	1 12	1 5	_	_	4 5	Jacksonville, FL Miami, FL	216 65	122 42	63 13	17 4	4 4	10 2	12 2
Lowell, MA	12	8	3	1	_	_	_	Norfolk, VA	55	32	14	5	2	2	3
Lynn, MA	6	4	_	2	_	_	_	Richmond, VA	57	36	14	6	1	_	_
New Bedford, MA New Haven, CT	18 24	16 17	2 2		_	 3	<u> </u>	Savannah, GA St. Petersburg, FL	54 48	39 31	9 10	2	1 2	3 2	4 4
Providence, RI	39	26	8	3	_	2	3	Tampa, FL	173	108	47	11	4	3	6
Somerville, MA	6	4	1	1	_	_	_	Washington, D.C.	100	58	24	5	5	8	5
Springfield, MA	57	38	10	4	1	4	5	Wilmington, DE	14	13	1	_	_	_	1
Waterbury, CT Worcester, MA	25 61	21 45	3 14	1 1	_	_ 1	2	E.S. Central	823	530	201	57	21	14	60
				112				Birmingham, AL	98	59	29	8	2 5	_ 1	3
Mid. Atlantic Albany, NY	2,056 43	1,390 28	473 11	1 12	42	39 3	108 3	Chattanooga, TN Knoxville, TN	101 90	74 52	20 25	1 9	3	1	8 6
Allentown, PA	35	22	5	7	1	_	_	Lexington, KY	62	39	18	3	1	1	2
Buffalo, NY	94	59	24	4	2	5	6	Memphis, TN	199	129	45	14	4	7	19
Camden, NJ Elizabeth, NJ	15 16	8 11	5 4	1	1	1	_ 3	Mobile, AL Montgomery, AL	77 47	47 38	19 4	8	1 1	2	6 7
Erie, PA	51	39	10	2	_	_	1	Nashville, TN	149	92	41	11	4	i	9
Jersey City, NJ	15	9	3	3	_	_	1	W.S. Central	1,400	866	357	104	37	36	66
New York City, NY	1,065	728	254	51	17	15	45	Austin, TX	96	61	21	9	2	3	8
Newark, NJ Paterson, NJ	27 23	17 13	7 8	2 1	1	_ 1	3 4	Baton Rouge, LA	67	32	16	10	9	_	_
Philadelphia, PA	307	182	74	28	13	10	15	Corpus Christi, TX	71	43	17	8	1	2	4
Pittsburgh, PA§	32	22	6	4	_	_	2	Dallas, TX El Paso, TX	185 34	111 22	49 7	17 2	4 3	4	8
Reading, PA Rochester, NY	26 133	22 95	2 30	1 3	 5	1	1 14	Fort Worth, TX	134	84	42	2	_	6	6
Schenectady, NY	26	23	3	_	_	_		Houston, TX	387	232	102	26	12	15	20
Scranton, PA	24	22	2	_	_	_	4	Little Rock, AR New Orleans, LA ¹	64 U	40 U	15 U	7 U	 U	2 U	1 U
Syracuse, NY	69	48	18	1	_	2	5	San Antonio, TX	214	139	55	16	3	1	10
Trenton, NJ Utica, NY	21 15	15 13	2 1	1 1	2	1	_	Shreveport, LA	55	36	11	5	2	1	5
Yonkers, NY	19	14	4	1	_	_	1	Tulsa, OK	93	66	22	2	1	2	4
E.N. Central	2,035	1,377	444	120	39	54	115	Mountain Albuquerque, NM	971 100	634 65	232 27	53 4	34 2	18 2	58 4
Akron, OH	38 36	31 30	5 5	1 1	_	1	_ 1	Boise, ID	57	41	7	6	2	1	3
Canton, OH Chicago, IL	361	226	87	23	13	12	31	Colorado Springs, CO	73	52	17	2	1	1	2
Cincinnati, OH	77	49	21	3	2	2	7	Denver, CO Las Vegas, NV	72 230	42 146	24 66	5 11	<u> </u>	1	9 14
Cleveland, OH	246	178	48	13	2	5	8	Ogden, UT	32	25	5		1	1	3
Columbus, OH Dayton, OH	194 128	133 92	38 23	16 9	2 1	5 3	8 6	Phoenix, AZ	148	85	38	9	11	5	9
Detroit, MI	163	86	54	9	7	7	13	Pueblo, CO	28	16	7	4	1	_	1
Evansville, IN	56	40	11	4	1	_	7	Salt Lake City, UT Tucson, AZ	100 131	68 94	20 21	5 7	7 3	_ 6	11 2
Fort Wayne, IN Gary, IN	69 14	47 5	15 2	3 2	1 2	3 2	4	Pacific	1,254	870	270	71	20	23	76
Grand Rapids, MI	39	27	7	3	2	_	4	Berkeley, CA	1,254	10	4		_		/ 6
Indianapolis, IN	157	101	37	11	3	5	8	Fresno, CA	67	44	14	6	2	1	3
Lansing, MI	39	34	5	_	_	_	1	Glendale, CA	U	U	U	ñ	U	U	U
Milwaukee, WI Peoria. IL	104 69	66 49	28 10	8 4	_	2 4	2 6	Honolulu, HI Long Beach, CA	84 60	63 37	12 16	5 3	2 2	2	10 8
Rockford, IL	47	34	10	3	_	_	1	Los Angeles, CA	Ü	Ü	Ü	Ü	Ū	Ū	Ü
South Bend, IN	57	42	12	1	_	2	1	Pasadena, CA	17	10	5	1	_	1	3
Toledo, OH Youngstown, OH	84 57	60 47	18 8	4 2	1	1	4 3	Portland, OR Sacramento, CA	121 198	79 130	28 50	10 12	1 4	3 2	6 10
_								San Diego, CA	176	128	32	8	3	5	8
W.N. Central Des Moines, IA	512 62	347 46	106 14	21 1	18 1	20	34 6	San Francisco, CA	44	31	9	2	_	2	2
Duluth, MN	35	26	6	2		1	2	San Jose, CA	171	121	32	12	3	3	11
Kansas City, KS	25	15	8	1	1	_	6	Santa Cruz, CA Seattle, WA	26 109	22 72	3 30	1 5	_ 1	_ 1	2 8
Kansas City, MO	86	58	18	3	5	2	5	Spokane, WA	53	37	11	3	1	1	3
Lincoln, NE Minneapolis, MN	35 60	26 30	7 11	 5	2 7	7	1 3	Tacoma, WA	114	86	24	3	1	_	2
Omaha, NE	58	42	10	3	_	3	2	Total	10,651**	7,044	2,454	645	251	256	605
St. Louis, MO	36	20	11	2	_	3	3								
St. Paul, MN	40 75	31 53	8 13	4	_	1 3	1 5								
Wichita, KS	/5	ეკ	13	4		3	<u> </u>	l							

U: Unavailable. —:No reported cases.

* Mortality data in this table are voluntarily reported from 122 cities in the United States, most of which have populations of ≥100,000. A death is reported by the place of its occurrence and by the week that the death certificate was filed. Fetal deaths are not included.


† Pneumonia and influenza.

§ Because of changes in reporting methods in this Pennsylvania city, these numbers are partial counts for the current week. Complete counts will be available in 4 to 6 weeks.

¶ Because of Hurricane Katrina, weekly reporting of deaths has been temporarily disrupted.

**Total includes unknown ages.

FIGURE I. Selected notifiable disease reports, United States, comparison of provisional 4-week totals November 17, 2007, with historical data



Notifiable Disease Data Team and 122 Cities Mortality Data Team

Patsy A. Hall

Deborah A. Adams Rosaline Dhara Willie J. Anderson Carol Worsham Lenee Blanton Pearl C. Sharp

^{*} No measles cases were reported for the current 4-week period yielding a ratio for week 46 of zero (0).

† Ratio of current 4-week total to mean of 15 4-week totals (from previous, comparable, and subsequent 4-week periods for the past 5 years). The point where the hatched area begins is based on the mean and two standard deviations of these 4-week totals.

The Morbidity and Mortality Weekly Report (MMWR) Series is prepared by the Centers for Disease Control and Prevention (CDC) and is available free of charge in electronic format. To receive an electronic copy each week, send an e-mail message to listserv@listserv.edc.gov. The body content should read SUBscribe mmwrtoc. Electronic copy also is available from CDC's Internet server at http://www.cdc.gov/mmwr or from CDC's file transfer protocol server at ftp://ftp.cdc.gov/pub/publications/mmwr. Paper copy subscriptions are available through the Superintendent of Documents, U.S. Government Printing Office, Washington, DC 20402; telephone 202-512-1800.

Data in the weekly *MMWR* are provisional, based on weekly reports to CDC by state health departments. The reporting week concludes at close of business on Friday; compiled data on a national basis are officially released to the public on the following Friday. Data are compiled in the National Center for Public Health Informatics, Division of Integrated Surveillance Systems and Services. Address all inquiries about the *MMWR* Series, including material to be considered for publication, to Editor, *MMWR* Series, Mailstop E-90, CDC, 1600 Clifton Rd., N.E., Atlanta, GA 30333 or to *www.mmwrq@cdc.gov*.

All material in the MMWR Series is in the public domain and may be used and reprinted without permission; citation as to source, however, is appreciated.

Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of Health and Human Services.

References to non-CDC sites on the Internet are provided as a service to MMWR readers and do not constitute or imply endorsement of these organizations or their programs by CDC or the U.S. Department of Health and Human Services. CDC is not responsible for the content of these sites. URL addresses listed in MMWR were current as of the date of publication.

☆U.S. Government Printing Office: 2008-723-026/41062 Region IV ISSN: 0149-2195